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Abstract 
Eosinophilic esophagitis (EoE) is a rare immune-mediated illness with symptoms that range from 
difficulty swallowing to food impaction of the esophagus. Most published studies have been documented 
among patients residing in cool regions with significant annual rainfall. No published studies to our 
knowledge have been performed examining the healthcare utilization trends of EoE in Nevada. Utilizing 
two unique databases, the factors associated with EoE healthcare utilization patterns in Nevada were 
examined. All analyses were performed in R version 3.5.1. This study included a demographic and 
regional analysis identifying risk factors associated with having an EoE healthcare visit in Nevada. 
Several trends complemented those seen in other EoE studies including increased utilization among male 
and pediatric subgroups, as well as those of Caucasian descent. In the second part of the study, clinical 
EoE comorbidities among subgroups were identified. While this disease typically has a well-documented 
relationship with atopic illness, the comorbidities identified in Nevada were largely gastric in nature; 
indicating a trend of late-stage diagnoses of the disease. Treatment by region differed significantly, 
pointing to a lack of consistency of EoE knowledge among healthcare providers. Data from a small cohort 
of EoE positive pediatric patients from a local clinic (n=59) were also obtained. This clinical EoE subset 
was used to complement the hospital utilization database in order to identify common sensitization 
patterns among the pediatric population. Surprisingly, this population was largely sensitized to 
aeroallergens, as opposed to the common food allergens reported in the literature. This indicates that 
treatment approaches for this condition in Nevada may be unique to those found in other regions. The 
final part of this study examined the financial impact of EoE healthcare utilization in Nevada. The cost of 
EoE was significantly greater for the pediatric subgroup as well as those receiving treatment in the 
Southern Nevada region. Lastly, in order to gain a better understanding of cost relative to similar chronic 
inflammatory diseases, a comparison was performed between EoE, Crohn’s disease and Celiac disease. 
Significant differences in cost and utilization patterns existed by gender, age and healthcare setting. 
Findings from this study fill an important gap in EoE knowledge in this region. Improved physician and 
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public health education for treatment is critical as the sensitization patterns in Nevada appear unique 
relative to other regions. Early identification of EoE diagnosis may improve knowledge and treatment 
among patients and providers in Nevada. 
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Chapter 1: Background Literature Review of Eosinophilic Esophagitis 
1.1 Eosinophilic Esophagitis 
 Eosinophilic Esophagitis (EoE) was first described as a rare chronic condition in 1978 (Landres, 
Kuster, & Strum, 1978). In less than 50 years, this disease has progressed from a rare case-reportable 
condition to a disease commonly observed in emergency rooms and endoscopy centers in Western 
populations  (Dellon & Hirano, 2018; Prasad et al., 2011). Eosinophilic esophagitis is an immune-
mediated allergic disease characterized by a dysfunctional esophagus and the presence of > 15 
eosinophils per high-power field (HPF) in the esophageal mucosa on esophageal biopsy (Dellon & 
Hirano, 2018; Longitudinal, Structural, & Models, 2015). Treatment options are limited, and several risk 
factors increase the odds of developing EoE.  The most common hypothesis that describe the increased 
incidence includes an increase in atopic diseases such as asthma, atopic dermatitis, allergic rhinitis, and 
food allergies observed in Western populations (Dellon, 2014).  This disease is becoming increasingly 
recognized, due to both increased incidence and improved detection methods, however, many questions 
remain unanswered (Kerlin, Jones, Remedios, & Campbell, 2007).   
1.2 Clinical Presentation of the Disease  
 Eosinophilic esophagitis can present at any age, but tends to be male predominant and is most 
common in Caucasian patients compared to other races (Dellon, 2014). Clinical presentation of EoE is 
different in children and adults. In children, a failure to thrive is observed due to feeding intolerance, 
abdominal pain, food impactions, and vomiting (Ishimura et al., 2015). In adult patients, dominant 
symptoms include difficulty swallowing, food impaction, heartburn, and chest pain (Ishimura et al., 
2015).  In extreme cases food impaction can require a visit to the emergency room for an urgent 
endoscopy (Dellon, 2014). Eosinophilic esophagitis is one of the most frequent diseases identified as the 
cause of food impaction in emergency departments across the United States (Dellon, 2014). One study 
states that 46-63% of patients experiencing food impaction, or difficulty swallowing will ultimately 
receive a diagnosis of EoE (Dellon, 2014).   
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1.3 Diagnosis and Pharmacotherapy 
 Diagnosis of EoE is determined using several approaches.  If a patient previously diagnosed with 
gastroesophageal reflux disease (GERD) receives proton pump inhibitor (PPI) treatments that result in no 
response, EoE is suspected and an endoscopy is performed (Ishimura et al., 2015).  During the endoscopy, 
certain phenotypic findings can allude to EoE, including esophageal rings, commonly known as “feline” 
esophagus, where food impaction or rupture typically occurs (Hawari & Pasricha, 2007; Ishimura et al., 
2015). A biopsy is performed during the endoscopy; an EoE diagnosis is made if there are >15 
eosinophils/HPF in the biopsy (Ishimura et al., 2015).  If the patient is not already on therapy for 
gastroesophageal reflux, the patient is introduced to a PPI treatment. If therapy results in improvement of 
symptoms and <15 eos/hpf, then it is termed “PPI-responsive esophageal eosinophilia” and PPI therapy is 
used as ongoing treatment (D’Alessandro, 2015). If the PPI treatment does not garner a response and the 
eosinophilia is persistent, the patient is diagnosed with “PPI unresponsive EoE” and put on a steroid 
regimen, or a specific elimination diet (D’Alessandro, 2015).   
 Adults are put on a selective food elimination diet by a gastroenterologist and expected to follow 
the recommendations with little to no guidance. In pediatric patients, determining which food is an 
allergenic culprit is priority.  This allows for less nutritional deficiency and growth failure, which may 
happen in young children placed on a broadly restrictive diet (Spergel et al., 2009). Allergenic foods may 
be determined by either skin testing, patch testing, and/or individual removal of each food. Adult and 
pediatric patients are expected to remain on the elimination diet for life after the disease enters remission 
stages. If neither PPI or elimination diet result in a reduction of symptoms of EoE, the patient is placed on 
an inhalational topical steroid to reduce swelling (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017). 
Since this is a chronic disease with no cure, relapse most often occurs when patients discontinue drug 
therapy, or deviate from the prescribed elimination diet (Davis, 2018). 
1.4 Pathophysiology  
  The pathophysiology and etiology of the disease are not well-understood; therefore, studies 
present various hypotheses. Current hypotheses regarding the etiology of EoE include a possible familial 
3 
 
inheritance pattern.  In addition, damage to the epithelial layer of the esophagus via acid reflux may 
increase the danger of developing EoE.  This damage may allow the inappropriate contact of either a food 
or aeroallergen to the mucosal layer of the esophagus initiating an allergenic response; which is normally 
prevented by the epithelial barrier covering the luminal surface of the esophagus (Takashima S, Tanaka F, 
Otani K, Hosomi S, Nagami Y, Kamata N, Taira K, Yamagami H, Tanigawa T, Fukumoto S, Watanabe 
T, 2019).  After this contact an immune mediated response hypothesized to be driven by T helper 2 (TH2 
cells) with release of IL-5 is established which results in eosinophil infiltration to the esophagus (Aceves, 
2014).   TH2 cells also have the capability of producing IL-4 which is responsible for instructing B cells to 
isotype switch to allergic antibody IgE production (Thomas M. Runge, MD & Evan S. Dellon, MD, 
2017).  The eosinophilic infiltration then results in the macroscopic observation of scaring/ring formation 
that is noted on endoscopy (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017).  Finally, the 
microbiome and early use of antibiotics is a newer hypothesis, proposing that children on long-term 
antibiotic regimens lose a significant portion of gut bacteria that may help regulate allergic diseases 
associated with EoE (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017).  These hypotheses continue 
to be investigated in the gastroenterology and immunology fields as the mechanistic effects of EoE are 
understood.  
1.5 Risk factors 
 Several risk factors exist for developing EoE including gender, race, preexisting allergies, season, 
and climate (Dellon, 2014). In a retrospective study performed at the University of North Carolina by 
Sperry et al., 208 EoE records were identified and stratified by race and gender (Sperry, Woosley, 
Shaheen, & Dellon, 2015). The mean age was 25.7 yrs. and the participants spanned from 6 months to 78 
years, with 50% of the individuals under the age of 18 (Sperry et al., 2015). Of the 208 records identified, 
76% were male and 82% were Caucasian, which aligns with other population studies performed 
(Iwanczak et al., 2011; Longitudinal et al., 2015; Molina-Infante et al., 2018; Warners et al., 2018).  
While there are reported differences between gender and race, the reason for this is unknown (Sperry et 
al., 2015). Additionally, there are typically no significant differences in endoscopy findings or 
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symptomology between adult males and females, or among different races/ethnicities diagnosed with EoE 
(Sperry et al., 2015).  
 Food and aeroallergens tend to exacerbate the symptoms of EoE. The most common food 
allergens reported are milk, eggs, soy, wheat, beef, and rye (Durrani, Mukkada, & Guilbert, 2018; Nielsen 
& Husby, 2007).  Other studies argue that aeroallergens are to blame for the development and 
symptomology of EoE. Armentia et al. identified 129 EoE adult patients who agreed to skin-prick tests 
for various aeroallergens (Armentia et al., 2018). Grass was identified as the predominant aeroallergen in 
the group, specifically Bermuda in 36.4% of cases and rye grasses in 27.1% of cases (Armentia et al., 
2018) Several tree pollens contributed as well, including pollen from olive trees in 17.1% of cases and 
peach trees in 11.6% of cases, were identified as triggers of EoE symptoms (Armentia et al., 2018).  
 Regional and seasonal variation of EoE is also present in many studies (Hurrell, Genta, & Dellon, 
2012; Iwanczak et al., 2011). Typically, the prevalence of EoE is higher in Northeastern and urban areas, 
as well as in cold and dry zones (Hurrell et al., 2012; Longitudinal et al., 2015). Wang et al. reports that 
significantly fewer new EoE patients are diagnosed in winter (17.9% of cases diagnosed) compared to fall 
(24.8% of cases diagnosed), spring (27.8% of cases diagnosed), and summer (29.5% of cases diagnosed) 
(Wang, Gupta, & Fitzgerald, 2007). In a study performed by Almansa et al., the same pattern was 
identified. Significant increases of EoE patients were seen in spring and summer months (68.3% of cases 
diagnosed; <0.001) when compared to fall and winter months (31.7% of cases diagnosed; 0.019) 
(Almansa et al., 2009).  
1.6 Genetic Components of the Disease 
 While this is not the focus of this study, weak evidence exists of potential genetic links. Martin et 
al. reports that EoE susceptibility may exist due to synergistic interactions between genetic loci: thymic 
stromal lymphopoietin (TSLP) and calpain 14 (CAPN14) (Martin et al., 2017). This study alludes to 
potential research that could aid in identifying patient-specific therapeutics, or could help predict EoE 
susceptibility (Martin et al., 2017).  
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 Due to the rare nature of the disease it is currently unknown whether there is a family history 
component. Some studies indicate that if a family history of atopy or eosinophilic diseases exists, then 
risk of EoE may be increased (Sorser, Barawi, Hagglund, Almojaned, & Lyons, 2013). Other studies 
report using whole genome sequencing to identify possible genes that may contribute to the development 
of EoE in adult and pediatric patients (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017). Finally, 
several genetic/inherited connective tissue disorders have been associated with EoE, including Loeyt-
Dietz syndrome (LDS), Marfan syndrome type II, and Ehlers-Danlos syndrome (Davis, 2018). 
1.7 Comorbidities 
 The most well-described comorbidities for EoE include atopic disorders such as asthma, allergic 
rhinitis, and atopic dermatitis, to name a few (Mohammad et al., 2017).  Eosinophilic esophagitis is an 
immune-mediated disease, therefore, the presence of other allergic disorders mediated by 
immunoglobulin E (IgE) is possible.  The presence of these diseases may exacerbate the symptoms of 
EoE. Studies report that 50-80% of patients diagnosed with EoE have a history of atopic illness (Ridolo et 
al., 2012).  In a single-site study of 449 patients, Mohammad et al. reports that 77.5% (n = 348) of 
patients with EoE in the United States suffer from at least one atopic comorbidity (Mohammad et al., 
2017).  Allergic rhinitis was prevalent in 61.9% of the EoE population, followed by asthma (39.0%), and 
atopic dermatitis (46.1%) (Mohammad et al., 2017).   
 Interestingly, a study performed in Australia identified a dichotomy between food and inhalant 
allergens using patch testing (on n = 33/45 EoE positive patients) and skin prick tests (on n = 45/45 EoE 
positive patients) (Sugnanam et al., 2007). Younger patients showed an increased IgE when exposed to 
food patch testing, while older patients showed a higher sensitization to inhalant allergens (Sugnanam et 
al., 2007). In Midwestern Spain, rhinoconjunctivitis (62%), asthma (52%), and food allergies (23%) were 
among the highest reported comorbidities in patients with EoE (Molina-Infante et al., 2018).      
1.8 Rates Reported Internationally and Nationally 
 Countries such as Poland, the Netherlands, Spain, Egypt, Japan, and the United States have 
published large scale population studies and exposed many common factors about the disease (Fouad, 
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Fouad, Mokareb, Mohamed, & Abdel-Rehim, 2018; Ishimura & Kinoshita, 2018; Iwanczak et al., 2011; 
Molina-Infante et al., 2018; Warners et al., 2018).  
 A 5-year pediatric patient study in Poland identified 84 records (23.8% female and 76.2% male) 
of EoE across ten gastroenterology centers in pediatric patients who had undergone esophageal 
endoscopies (n = 35,631) (Iwanczak et al., 2011). The most frequent symptoms of EoE in the patients 
included feeding aversion, regurgitation or vomiting, abdominal pain, dysphagia, and chest pain 
(Iwanczak et al., 2011). Further, EoE was diagnosed in all pediatric ages (1-18 years) mainly during the 
spring (45.2% of cases diagnosed) and summer (28.5% of cases diagnosed) (Iwanczak et al., 2011). 
 The Netherlands reports a rapid increase in EoE over the past 20 years. In a single-site study of 
the Dutch pathology registry, 5,080 records of EoE out of 11,288 endoscopy records were described 
(Warners et al., 2018).  The incidence of EoE had increased nearly 200-fold from 1996 to 2015 
(0.01/100,000; 95% CI: 0.00-0.02 to 2.07/100,000; 95% CI: 2.05-2.23), whereas the endoscopy rates had 
only tripled in the same timeframe (Warners et al., 2018). No seasonal variation was noted, however, 
incidence was higher in males than females (3.02/100,000; 95% CI: 2.66-3.41 versus 1.14/100,000; 95% 
CI: 0.93-1.38, respectively) and higher in adults than children (2.23/100,000; 95% CI: 1.99-2.49 and 
1.46/100,000; 95% CI: 1.09-1.91, respectively) (Warners et al., 2018).  
 Spain also reports increased incidence in EoE over the past decade. In a large EoE geographical 
study in Midwestern Spain, 196,363 medical records were examined and newly diagnosed adult EoE 
cases between January 1, 2007 through December 31, 2016 were recorded (Molina-Infante et al., 2018). 
The annual incidence of EoE increased from 2.97/100,000 in 2007 to 13.72/100,000 in 2016 (Molina-
Infante et al., 2018).  Molina-Infante et al. (2017) did not report seasonal variation or race/ethnicity 
differences, but did report that incidence was significantly higher in males (73% of cases diagnosed) than 
females (27% of cases diagnosed) (Molina-Infante et al., 2018).  
 Contrary to Poland, the Netherlands, and Spain, studies from Egypt and Japan report lower 
incidence rates. In a single-center, cross-sectional study conducted in Egypt from 2013-2015, 476 adult 
patients with upper gastrointestinal symptoms underwent endoscopies (Fouad et al., 2018). Of those 
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observed patients, only four (1.87%) had a diagnosis of EoE (Fouad et al., 2018). Additionally, in Japan, 
a study was performed in 2010 that examined medical records of patients who had undergone an upper 
gastrointestinal endoscopy (n = 23,346); of those patients only four were diagnosed with EoE (Ishimura 
& Kinoshita, 2018). In 2017, using identical criteria, a follow-up multi-center prospective study was 
performed (n = 17,324), of those, eight individuals were diagnosed with EoE (Ishimura & Kinoshita, 
2018). While the rates were lower, the EoE diagnosed male to female ratio (4 male:1 female) was similar 
to other studies performed (Ishimura & Kinoshita, 2018).  
 Although there was a slight increase in incidence of EoE in the clinics observed in Japan, the 
rates are still much lower than those in Western populations (Ishimura & Kinoshita, 2018).  Several 
studies note a difference of EoE incidence and symptomology in Asian populations when compared to 
Caucasian populations (Ishimura et al., 2015; Ito, Fujiwara, Kojima, & Nomura, 2015). A possible reason 
includes the difference in diet between the two populations. The Food and Agriculture Organization of the 
United Nations reports the total vegetable supply in Eastern Asia is more than double what is distributed 
in North America, while the exact opposite is true for the total meat supply (Ito et al., 2015).   
 Several EoE studies have been published in the United States. A nationwide retrospective study 
on 26 major healthcare systems was performed using a commercial database (Longitudinal et al., 2015).  
Over 30 million individual, adult medical records were examined and the report contained 7,840 
individual records with a diagnosis of EoE from 2010-2015 (25.9/100,000; 95% CI: 25.3-26.5) 
(Longitudinal et al., 2015). A majority of the records were male (61.9% of records), Caucasian (89.3% of 
records), and ages ranged from 18-65 years (Longitudinal et al., 2015). Hurrell et al. (2012) examined 
seasonal variation in the United States using the Köppen-Geiger climate zones, which stratifies zip codes 
into main climate type A – tropical, B – arid, C – temperate, D – cold, E – polar (Hurrell et al., 2012). 
Results showed that the odds of developing EoE are 39% higher in cold (D) climate zones (OR = 1.39; 
95% CI: 1.34-1.47) compared to the tropical zones (OR = 0.87; 95% CI: 0.71-10.8) (Hurrell et al., 2012).  
Finally, Davis (2018) reports that EoE is most commonly found in rural and suburban areas when 
compared to metropolitan areas (Davis, 2018).  
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1.9 Overall Impact of EoE 
 While the effects of EoE on the adult and pediatric populations has been well studied, the cost of 
EoE is seldom reported.  One study used the IMS LifeLink® PharMetrics Health Plan Claims Database to 
examine the healthcare utilization and costs of EoE in the United States (Jensen, Kappelman, Martin, & 
Dellon, 2015). Median costs for EoE included ~$2,000 for outpatient visits, ~$150 per endoscopic 
treatment, and ~$300 per pharmacy claim for PPI medication (Jensen et al., 2015). The overall prevalence 
estimate for the US was between $503 million to $1.4 billion per year, depending on the treatment, 
procedures performed, and hospital setting utilized by the patient (Dellon, Jensen, Martin, Shaheen, & 
Kappelman, 2015).   
 Several studies have identified negative quality of life (QoL) impacts from eosinophilic 
esophagitis in both adult and pediatric patients. In a multi-center cross-sectional study, Lucendo et al. 
used the Adult Eosinophilic Esophagitis Quality of Life (EoE-QoL-A) questionnaire to identify and 
quantify determinant factors of health-related QoL in EoE patients (Lucendo, Arias-González, Molina-
Infante, & Arias, 2017).  The total response was n = 170 and was predominantly male (73.5%) (Lucendo 
et al., 2017). Disease anxiety (2.13 + 0.9 points), choking anxiety (1.97 + 1.1 points), social impacts from 
EoE (1.77 + 1.1 points), and diet/eating impacts (1.68 + 0.9 points) exhibited the highest mean scores and 
were the most important factors, whereas emotional impact had the lowest mean score (1.15 + 0.9) on the 
questionnaire (Lucendo et al., 2017). In a cross-sectional study performed in the United Kingdom, the 
Short Form-36 (SF-36) questionnaire was utilized for adult EoE patients (n = 88 total; 44 EoE patients; 44 
matched controls) (Hewett et al., 2017). Patients who took the SF-36 questionnaire had higher rates of 
antihistamine and steroid use than controls and patients with EoE reported a statistically significant lower 
mental QoL (Hewett et al., 2017). 
 The pediatric population is also significantly affected by EoE. A group of pediatric patients was 
examined (n = 35, mean was 10 years old) and reported vomiting (71.4% of cases) and abdominal pain 
(51.4% of cases) as the top symptoms experienced (Rodrigues Mariano De Almeida Rezende et al., 
2014). While many of the children were aware of the disease and maintained a good nutritional state 
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(82.8% of cases), over two-thirds of the population exhibited food allergies or pollen sensitivities 
(Rodrigues Mariano De Almeida Rezende et al., 2014). The pediatric patients treated in this study did not 
exhibit alterations in growth curves, which aligns with other pediatric studies performed overseas 
(Rodrigues Mariano De Almeida Rezende et al., 2014). This is likely due to disease isolation in the 
esophagus (Rodrigues Mariano De Almeida Rezende et al., 2014).  Unfortunately, the same cannot be 
said for the psychosocial aspects of pediatric patients diagnosed with EoE. Franciosi et al. (2012) 
conducted focus interviews on EoE children from 2-18 years old and the respective parents in an attempt 
to identify concerns related to EoE-specific health related QoL (Franciosi et al., 2012).  The concerns of 
the parents included “worry about symptoms and illness” as well as diet and medication adherence, 
whereas the pediatric patients were more concerned with “being different that family and peers” as well 
as difficulties eating food (Franciosi et al., 2012).      
1.10 Eosinophilic Esophagitis in Nevada 
 This dissertation presents an extensive literature review, alongside epidemiological methods and 
various statistical testing to describe the EoE population in the state of Nevada. To our knowledge, no 
published studies have been performed that examine eosinophilic esophagitis in the state of Nevada. 
Therefore, the studies presented here sought to fill several gaps in the literature and covers several 
objectives. In Chapter 2 the distribution of EoE in Nevada and the risk factors associated with this disease 
in the state is described. Chapter 3 discusses the comorbidities associated with EoE in relation to 
demographic subgroups. Additionally, in Chapter 3, a histologically positive pediatric EoE clinical subset 
was provided by University of Nevada, Reno School of Medicine (UNR SOM) to help determine aero- 
and food sensitizations in the pediatric EoE population. Finally, in Chapter 4, the cost of healthcare 
utilization of EoE diagnosed adult and pediatric records was examined using service, procedure, and 
diagnosis codes. These results were compared to two well-known inflammatory conditions to put the 
impact of EoE into context. Finally, a summary of the findings described, and public health implications 
are presented in Chapter 5.  
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1.11 Summary of Database and Ethical Considerations 
 Data for the studies presented in Chapters 2 – 4 were provided by the Center for Health 
Information Analysis (CHIA) for Nevada. This center holds comprehensive health care data records for 
all causes from multiple healthcare settings in the state including: ambulatory surgery centers (ASC), 
emergency departments (ED), inpatient centers (IP), and other outpatient settings (THOS) and is Health 
Insurance Portability and Accountability Act (HIPPA) compliant. These datasets contained over 300 
variables and were thus reduced to include only the necessary variables. Each set of variables used are 
described in each study chapter. The codebook produced for these studies is included in Appendix A. 
 Prior to the start of the study a Limited Data Set Use Agreement (LDSUA) was approved and 
subsequently signed by all parties participating in the project. The LDSUA is provided in Appendix B. 
This project, and all subsequent studies in this dissertation, were deemed exempt for secondary data 
analysis by the UNLV Office of Research Integrity Human Subjects Board due to the de-identified nature 
of the data on June 19th, 2018.  
 The approval process and description of the clinical dataset provided by UNR SOM is presented 
in Chapter 3 and the approval documentation is presented in Appendix C.  
   
 
 
 
 
 
 
 
 
 
11 
 
Chapter 2: Factors Associated with Eosinophilic Esophagitis in Nevada 
 
Abstract 
 Eosinophilic esophagitis (EoE) is a rare disease not well-characterized in the state of Nevada. 
Five-years of hospital utilization data (2013-2017) yielded over 2,000 EoE records across all hospital 
settings. Multiple logistic regression was utilized to determine factors associated with an EoE visit in 
Nevada. Males were 2.93 times more likely (95% CI: 2.53, 3.41; P < 0.001) to have an EoE visit when 
compared to females. Older age was a significant factor; for each additional year in age the odds of 
having an EoE visit increased by 30% (Odds ratio (OR) = 1.30, 95% CI: 1.28, 1.31; P < 0.001). Admit 
year was also significant; records in 2016 had 26% higher chance of an EoE event when compared to 
records in 2013 (OR = 1.26, 95% CI: 0.99, 1.59, P = 0.05). Overall, race was not a significant factor (P > 
0.05). Most interestingly, individuals living in the Northern region of Nevada have 1.95 higher odds of an 
EoE visit than their Southern counterparts (OR = 1.95, 95% CI: 1.68, 2.26; P < 0.001). This study seeks 
to improve the understanding of the factors associated with the healthcare utilization pattern of this rare 
condition in Nevada. 
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Introduction 
 Eosinophilic esophagitis (EoE) is a rare immune-mediated illness diagnosed histologically via 
endoscopy (>15 eosinophils/high-power field) (1, 2). In adults, symptoms arise in the form of persistent 
heartburn, difficulty swallowing, and food impaction; among the pediatric population, symptoms often 
include: vomiting, nausea, abdominal pain, failure to thrive and, more rarely, food impaction (Spergel et 
al., 2009). Current literature indicates that this global disease affects males two times more often than 
females and individuals of Caucasian descent are at greater risk compared to other racial groups (3, 4).  
 Several regional and climate studies performed in the United States characterize the EoE 
population; the most notable include studies performed Dellon et al. (2014) and Hurrell et al. (2012). 
Dellon et al. (2014) reports the prevalence of EoE as 56.3/100,000 persons, with the highest prevalence 
located in the Midwest (33.6/100,000 persons) and the South (32.1/100,000 persons), followed by the 
East (19.1/100,000 persons), and the West (15.2/100,000 persons) (Dellon, Jensen, et al., 2015). 
Additionally, a climate study performed by Hurrell et al. (2012), reports that the odds of developing EoE 
is 39.0% higher (OR = 1.39; 95% CI: 1.34, 1.47) in cold zones, 27.0% higher in arid zones (OR = 1.27; 
95% CI: 1.19, 1.36), and lowest in tropical zones (OR = 0.87; 95% CI: 0.71, 1.08) when compared to 
temperate regions (Hurrell et al., 2012).  Given the published regional and climate results, a higher than 
expected number of EoE records were identified in Nevada (n = 2,296) over five years (2013-2017).  
 Given the relationship between EoE and atopic disease, it is pertinent that region is considered a 
factor in this study (Moawad et al., 2010). The state of Nevada is unique in that the federal government 
owns nearly 85% of the land, the climate is hot and dry year-round, and the two largest cities (Reno and 
Las Vegas) have been named the “Driest Cities in the United States” for several years (6, 7). Patel et al., 
examined five pollen collection sites in the city of Las Vegas, Nevada and concluded that significant 
composition and concentrations of pollen existed at all five sites (Patel et al., 2018). Using this 
knowledge, it is reasonable to assume that different climatic regions of the state would also exhibit 
different allergens year-round, potentially increasing the risk of an EoE event in specific locations. 
Further, the Northern region of the state experiences colder than average temperatures in the winter 
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(January 25oF/-3.9oC) and summer (July 58oF/14oC) when compared to the Southern region (January 
39oF/-3.8oC and July 81oF/27oC, respectively), which could indicate longer a pollination season in the 
Southern region. All such factors may play a critical role in the association of EoE and the Nevadan 
population.  Objectives of this study include: (1) describing the EoE population in the state of Nevada; 
and (2) determining existing patterns of EoE in Nevada by region using a large hospital utilization 
database.  
Methods 
Population 
The initial database yielded over 12 million hospital utilization records over five years (2013-
2017) for the state of Nevada. Inclusion criteria for selection included healthcare records with primary (1) 
through quaternary (4) EoE diagnosis codes (ICD-9 = 530.13 or ICD-10 = K20.0) from all hospital 
settings. Only primary through quaternary diagnosis code records were considered “relevant” to the study, 
as EoE itself can often be a comorbidity (Durrani et al., 2018). Records were extracted and filtered to 
include Nevada residents exclusively, resulting in a total of 2,196 EoE records across all study years and 
hospital settings. 
Data collection and variable definition 
All hospital settings (ASC, ED, IP, and THOS) were merged into one dataset and included the 
following variables: patient zip code, race/ethnicity, age, gender, and admit year. The EoE records were 
grouped by Northern and Southern regions using zip codes extracted by the statistical software R using 
the CRAN “Zip code” package (Breen, 2012). Using the Nevada Governor’s office of Economic 
Development, cities located in the Northern Sierra and Northeastern Nevada regions were grouped as 
“Northern” and cities located in Central and Southern Nevada regions were grouped as “Southern” 
(Nevada Governor’s Office of Economic Development, 2018).  
Statistical analysis 
 Descriptive statistics were performed to identify frequency distributions of the EoE healthcare 
utilization population including age, gender, race/ethnicity, admit year, and region. As there was a highly 
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unequal distribution of EoE records (n = 2,196) respective to all other possible cause records (n = 
12,629,055), a random selection of non-EoE records were selected from the database for comparison; this 
allowed for subsequent modeling required to identify significant variables associated with an EoE 
healthcare visit. As each dataset by setting type differed in sample size, a 1:5 ratio was obtained using 
probability proportionate to size by setting. The sample size of the final dataset (including EoE records) 
was 13,079. Multiple logistic regression was subsequently performed to identify the odds of having an 
EoE visit versus “other cause” healthcare utilization visit. Demographics and hospital utilization 
characteristics were modeled with the dependent variable (EoE) which was coded as binary.  
 An initial model was run to determine significant univariate variables as well as to avoid 
multicollinearity. In the initial logistic regression model, all five variables were significantly associated 
with having an EoE visit (region, gender, race, age, and admit year; P < 0.05) and interaction between 
region by age as well as region by gender were significant (P < 0.001). The final logistic regression 
model included the main effects region, age, gender, race, admit year, as well as region*age, and 
region*gender. This was the most parsimonious model identified. Once the final model was selected, the 
effect size was determined using follow-up testing.  Adjusted odds ratios were generated to identify at-
risk factors for EoE healthcare utilization visits in the state of Nevada.  Finally, due to the significant 
interactions, data were stratified by region to determine differences between demographics and EoE by 
region and effect sizes were determined using follow-up testing. Regional odds ratios were calculated to 
identify at-risk factors for EoE healthcare utilization visits.  A P-value of less than 0.05 and the 95% CI 
were set for significance for all models and analyses were run using R version 3.1.5 (R Core Team, 2013).  
Results 
Statewide and regional demographic analysis 
 A total of 2,196 EoE records were extracted from the hospital utilization database. The mean age 
statewide was 33.2 years old (Standard Error (SE): 0.0017). Records listed as ‘male’ had a higher 
representation than females among EoE records (n = 1,398 (63.7%) versus n = 798 (36.3%), respectively) 
(Table 1). Table 1 shows that a majority of the EoE statewide records were patients of White/Caucasian 
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descent (n = 1,360, 61.9%), followed by 8.58% Hispanic/Other (n = 188), 2.41% of Native American, 
Alaskan, Asian or Pacific Islander (n = 53), and Black/African American (n = 99, 4.51%). This 
racial/ethnic breakdown was similar to all-cause records. 
 The total number of EoE records identified in Nevada was 2,196; the total number of records 
were similar between the Northern (n = 1,004, 45.7%) and Southern (n = 1,192, 54.3%) regions of the 
state (Table 1). The Northern region had a slightly higher mean age at 39.4 years old, whereas the mean 
age in the Southern region was lower at 27.8 years old (Table 1). Additionally, records listed as “male” 
were 14.6% and 38% higher than records listed as “female” when broken down by Northern and Southern 
regions, respectively (Table 1). White/Caucasian was the dominant racial/ethnic group in both regions (n 
= 633 (63%) and n = 705 (59.1%), respectively), followed by Hispanic/Other (n = 48 (4.8%) and n = 51 
(4.3%), respectively), Native American/Alaskan/Asian/Pacific Islander (n = 23 (2.3%) and n = 40 (3.4%), 
respectively), and Black/African American (n = 21 (2.1%) and n = 17 (1.4%), respectively) (Table 1). The 
demographic breakdown of the EoE records identified were similar throughout the CHIA database, with 
white/Caucasian (61.2%) as the most represented followed by Hispanic/other (11.82%).   
 
Table 1. Demographic Characteristics of Records with an EoE Discharge Diagnosis. 
Variable of Interest 
Overall 
(n = 2,196) 
Northern 
(n = 1,004) 
Southern 
(n = 1,192) 
Age (mean (SE)) 33.2 (0.46) 39.4 (0.60) 27.8 (0.64) 
Gender 
Female 798 36.30% 429 42.70% 369 31.00% 
Male 1398 63.70% 575 57.30% 823 69.00% 
Race/Ethnicity       
Native*  63 2.87% 23 2.30% 40 3.40% 
Black/African American 38 1.73% 21 2.10% 17 1.40% 
White/Caucasian 1338 60.93% 633 63.00% 705 59.10% 
Hispanic/Other 99 4.51% 48 4.80% 51 4.30% 
Unknown/Missing 658 29.96% 279 27.80% 379 31.80% 
Admit Year 
2013 357 16.26% 156 15.50% 201 16.90% 
2014 348 15.85% 168 16.70% 180 15.10% 
2015 422 19.22% 194 19.30% 228 19.10% 
2016 531 24.18% 238 23.70% 293 24.60% 
2017 538 24.50% 248 24.70% 290 24.30% 
*Native group includes: American/Alaskan/Asian/Pacific Islander 
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The number of EoE records per admit year across the state increased between 2013-2016 but 
decreased slightly in 2017 (Table 1). The records in the Northern region have steadily increased every 
year for the last five years (Table 1). The Southern region exhibited a decrease from 2013 to 2014 (1.8%) 
but increased continuously from 2014-2016, with a slight decrease from 2016-2017 (Table 1). When the 
distribution frequencies of age versus EoE diagnosis level were plotted, primary EoE diagnosis was 
heavily skewed to the left. This indicates that pediatric records were the highest reported as a primary 
diagnosis between 2013 and 2017.  
Statewide analysis 
  Region, age, gender, race, and admit year were all significant in the final adjusted model (P < 
0.05) (Table 2). In follow-up testing those in the Northern region of the state had 1.95 higher odds of 
having an EoE visit when compared to their Southern counterparts (OR = 1.95, 95% CI: 1.68, 2.26, P < 
0.001) (Table 2). For every year increase in age the odds of an EoE visit increased by 30% (P < 0.001, 
95% CI: 1.28, 1.31) (Table 2). Males were 2.93 times (P < 0.001, 95% CI: 1.28, 1.31) more likely than 
females to have an EoE visit (Table 2). Due to a small number of records listed as Native 
American/Alaskan, or Asian/Pacific Islander race, these racial groups were combined (n = 418). Only the 
group labeled “Unknown/Missing” remained significant (P = 0.02) during secondary analysis. It should 
be noted that visits with race listed as “Black/African American” had 23% lower odds (P = 0.35, 95% CI: 
0.45, 1.32) and those listed as “Non-white Hispanic” had 17% lower odds (P = 0.71, 95% CI: 0.67, 1.31) 
of an EoE visit when compared White/Caucasians, although these results were not significant (Table 2). 
Finally, the 2016 admit year was significant, with 1.26 higher odds (P = 0.05, 95% CI: 0.99, 1.59) of an 
EoE visit when compared to all visits reported in 2013 (Table 2).   
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Table 2. Multiple Logistic Regression of Factors Associated with EoE. 
Predictor OR 95% CI  P-value 
Region    
Northern 1.95 1.68, 2.26 <0.001 
Southern * * * 
Age (continuous) 1.30 1.28, 1.32 <0.001 
Gender           
Female * * * 
Male 2.93 2.53, 3.41 <0.001 
Race                        
Native1 0.83 0.54, 1.29 0.41 
Black/African American 0.77 0.45, 1.32 0.35 
White/Caucasian * * * 
Hispanic/Other 0.94 0.67, 1.31 0.71 
Unknown/Missing 1.22 1.04, 1.43 0.02 
Admit Year             
2013 * * * 
2014 1.07 0.83, 1.38 0.59 
2015 1.11 0.87, 1.42 0.39 
2016 1.26 0.99, 1.59 0.05 
2017 1.16 0.92, 1.47 0.21 
Interaction Effects    
Region*Age   <0.001 
Region*Gender   <0.001 
1Native group includes: American/Alaskan/Asian/Pacific Islander 
*Reference Group 
 
Regional analysis 
 Significant interaction effects indicate that logistic regression by region may reveal important 
demographic differences. Differences exist between age and EoE by location (P < 0.001). The odds of an 
EoE event increase 1.26 times per year in the Northern region (P < 0.001, 95% CI: 1.24, 1.28) and 1.36 
times per year in the Southern Region (P < 0.001, 95% CI: 1.33, 1.38) (Table 3). Differences also exist 
between gender and EoE by location. Males residing in the Northern region have 2.26 times higher odds 
(P < 0.001, 95% CI: 1.84, 2.78) of an EoE event than females residing in the same region. Additionally, 
males residing in the Southern region have 3.78 times higher odds (P <0.001, 95% CI: 3.03, 4.71) of an 
EoE event than females residing in the same region.  
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Table 3. Multiple Logistic Regression of Factors Associated with EoE Stratified by Region. 
 Northern Southern 
 OR 95% CI P-value OR 95% CI P-value 
Age (cont.) 1.26 1.24, 1.28 <0.001 1.36 1.33, 1.38 <0.001 
Gender       
Female * * * * * * 
Male 2.26 1.84, 2.78 <0.001 3.78 3.03, 4.71 <0.001 
*Reference group 
 
Discussion 
Statewide analysis 
 During analysis, a large sample of the primary EoE diagnoses in the last five years was in the 
pediatric age group (>1/3). Secondary analysis indicated that as age increases, the odds of an EoE visit 
statewide increased by 1.30 (P < 0.001, 95% CI: 1.28, 1.32), or 30% per year. This could be due to 
several factors. First, significant improvements in diagnostic methodologies and identification of this 
disease reported in the literature, particularly in the pediatric age group (Spergel et al., 2009). Second, 
unique to Nevada, Wong et al. explains that a large percentage of children in the state are sensitized to at 
least one outdoor allergen by the age of three (Wong, Wilson, Peele, & Hogan, 2012). Wong hypothesizes 
that the unique geographic features of the state may contribute to the heightened percentage of atopic 
disease (Wong et al., 2012).  These specific geographic factors in Nevada, such as lack of rainfall and 
increased atopic disease in young children, could be reasons for the heightened number of records 
observed in the state. Consistent with other reports, regional differences were also observed in this study. 
Upon further investigation, this finding supports current published data that indicates an increased 
prevalence of EoE in colder regions (Davis, 2018).  Further geographic and comorbid analysis could help 
explain the duality of the atopic diseases and EoE in the state of Nevada.  
 The records labeled as “males” in the database are nearly double the records labeled as “females,” 
which follows current trending reported in the United States and abroad (n = 1,398 (63.7%) versus n = 
798 (36.3%), respectively) (4, 13). Males had a higher EoE record representation than females in both the 
Northern and Southern regions as well (575 (57.3%) and 823 (69%), respectively) (Table 1). Gender was 
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statistically significant in the logistic regression model; males had nearly 3 times higher odds (OR = 2.93, 
P < 0.001, 95% CI: 2.53, 3.41) of an EoE visit than females (Table 2). Interaction effects further indicated 
that differences exist between EoE and gender by region (P < 0.001) (Table 2). Males in the Northern 
region of the state have 2.26 higher odds (P <0.001, 95% CI: 1.84, 2.78) of an EoE event than females 
and 3.78 higher odds (P < 0.001, 95% CI: 3.03, 4.71) of an EoE event than females in the Southern 
Region (Table 3).  
 Unfortunately, the results presented here do not allude to the pathological or genetic reasons why 
males are more prone to the illness than females, which is largely unknown in the EoE community 
(Sperry et al., 2015). The total male records pulled from the CHIA database differed slightly between the 
Northern and Southern regions (46.11% and 44.17%, respectively), however not enough to cause the high 
odds ratios observed across regions of the state. The literature reports males as upwards of 76% of all EoE 
visits reported (Sperry et al., 2015). Moreover, differences between demographics and EoE by region are 
also reported throughout the literature. One potential hypotheses for regional differences includes 
decreased humidity and rainfall in the western regions, compared to the southern region of the U.S. as 
well as increased allergy (Ally, Maydonovitch, Betteridge, Veerappan, & Moawad, 2015).  
 The most prevalent race included EoE records listed as ‘white/Caucasian’ (n = 1,360, 61.9%), 
followed by Hispanic (n = 124, 5.56%), Black/African American (n = 99, 4.51%), and Asian (n = 50, 
2.28%). The frequencies reported here are vastly different from other published reports. In a study 
performed in Southern California by Kim et al. (2015), the racial/ethnic breakdown of identified EoE 
records were much different from Nevada, where Hispanics had higher rates of EoE than any other group. 
Kim et al. (2015) reports the percentage breakdown of EoE records in CA as Hispanic (33%), 
white/Caucasian (31%), Asian (10%), and black/African American (8%) (Kim, Kim, & Sheikh, 2015). 
While according to the United States Census, the white/Caucasian group is dominant in Nevada (49.1%), 
a higher number of Hispanic/Latino and Asian records would be expected given the racial/ethnic 
composition of the state (United States Census Bureau, 2018). This could point to either a lack of access 
in Nevada for specific racial groups, or under/mis-diagnosis of EoE, both which require further in-depth 
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analysis. Race was significant in the logistic regression model and indicated that visits with race/ethnicity 
listed as “Unknown/Missing” had 1.22 higher odds (P = 0.02, 95% CI: 1.04, 1.43) of having an EoE visit 
when compared to white/Caucasian. No further conclusions can be made from this result. 
 The number of records per year, when compared to all-cause records, continues to increase. The 
only statistically significant year in the regression model was 2016, where the odds of an EoE record were 
1.26 times more likely than in 2013 (P = 0.05, 95% CI: 0.99, 1.59). While at the significance cutoff, this 
variable is importing in understanding the temporal nature of EoE in the state of Nevada. Reports indicate 
that the prevalence of EoE is increasing worldwide, both due to improvement of diagnostic techniques, 
but also due to the increase in atopic disease (Pawankar, 2014).  
Strengths and limitations 
  The main limitation for this study includes the inability to calculate a true prevalence rate 
because the data used does not account for repeat healthcare visits. Finally, a lack of reporting in the 
healthcare systems in Nevada was observed during analysis. A significant number of the records provided 
do not have a listed race/ethnicity listed but are at a significantly higher risk of an EoE outcome (P < 
0.001) (Table 2). Steps should be taken to improve the reporting system in Nevada to avoid this lack of 
documentation, particularly when such records indicate significance of a rare disease.  
 The strengths of this study include a large population size using hospital records as an alternative 
to more commonly used self-reported data. Hospital records have more sensitive information that 
individuals are not likely to provide in self-report survey situations. The data also represents all setting 
types in Nevada, detailing a broader image of the EoE population and the services utilized around the 
state. Finally, while the number of records between the Northern and Southern regions was similar, it is 
known that the Southern population is nearly double that of the Northern region. Indicating that more 
research needs to be done to understand why. 
Conclusions and implications 
 First identified in 1978, this disease is still in its infancy and methodologies are catching up to the 
increasing prevalence of the disease (1, 17). To our knowledge, this study is the first of its kind to 
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examine the characteristics of the rare disease Eosinophilic Esophagitis in the state of Nevada. The 
heightened number of records in pediatric patients over the years, double the representation of males 
compared to females, and a high propensity of white/Caucasian records are all widely reported results in 
observed EoE populations.  However, this study highlights geographic differences for both gender and 
age in this population. The effect of region on the EoE population in the state of Nevada, particularly in 
those with comorbid atopic disease, is currently unreported in the literature.   
 Additional studies would add to the developing knowledge base of EoE in Nevada. Studies 
examining comorbidities of EoE as well as potential food and aero-allergens would enhance 
understanding of this illness both regionally and statewide. Further, identification of important cost 
characteristics between pediatric and adult populations may expose gaps in medical care or coverage for 
these populations when compared to other immune-mediated diseases. 
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Chapter 3: Comorbidities, Sequela, and Atopic Disease Associated with EoE in Nevada 
 
Abstract 
 Given the relationship between eosinophilic esophagitis (EoE) and atopy, differences in climate 
could significantly impact the presence of this rare immune-mediated disease in select locations. We 
aimed to examine the comorbidities and sensitization associated with an EoE diagnosis in Nevada.  The 
study goal was two-fold: determine the most common EoE comorbidities or sequela in the state of 
Nevada using healthcare utilization records; and determine the most common food and aeroallergens in 
histologically positive EoE pediatric patients using sensitization data. Esophageal obstruction/stricture 
was at the top diagnosis reported in adults with EoE. Among pediatrics, the highest-ranking comorbidities 
included asthma, diseases of the stomach, duodenum, and intestine, allergies, and gastroesophageal reflux 
disease. Additionally, the top sensitizations reported in histologically positive EoE patients were largely 
pollen-related. Atopic disease and food allergen are commonly reported as a comorbid condition with 
EoE. In our data aeroallergen sensitization results from histologically positive pediatric EoE patients far 
exceeded those of food allergens. Incidences of esophageal stricture/obstruction in adults were also high 
indicating late diagnosis. Education about the prevalence of aeroallergen sensitization in this population 
may result in earlier diagnoses and help reduce morbidity and cost from this disease. 
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Introduction 
 The prevalence of eosinophilic esophagitis (EoE) continues to increase in parallel with atopic 
disease (Davis, 2018). Symptoms vary in adult and pediatric patients, ranging from difficulty swallowing, 
food impaction, abdominal pain, and persistent heartburn (Dellon & E.S., 2012). Diagnostic methods for 
EoE are invasive and require endoscopic biopsy with the presence of >15 eosinophils per high-power 
field (HPF) regardless of age group (Dellon & E.S., 2012). To our knowledge, comorbidities and sequela 
associated with EoE in the state of Nevada have not been examined.  
 In Australia, EoE is often seen in conjunction with allergic rhinitis (93.33% of patients), followed 
by asthma, atopic eczema, and anaphylaxis (Sugnanam et al., 2007). Investigators in Brazil reports 
allergic rhinitis as the most common comorbidity, identified in 74.2% of EoE cases, with asthma and 
atopic dermatitis following closely behind (Rodrigues Mariano De Almeida Rezende et al., 2014).  In the 
United States, Massachusetts, Ohio, New York, and Illinois studies all reported allergic rhinitis as the 
most common comorbidity (70%, 61.9%, and 36%, 58.9%,  respectively), followed by food allergies, 
asthma, and atopic dermatitis (Fahey, Robinson, Weinberger, Giambrone, & Solomon, 2017; Kagalwalla 
et al., 2017; Letner, Farris, Khalili, & Garber, 2018; Mohammad et al., 2017). Illinois also noted allergic 
conjunctivitis as a comorbid condition (Kagalwalla et al., 2017). 
 While food allergies, allergic rhinitis and asthma are relatively common in patients diagnosed 
with EoE, food allergens are most often reported. Investigators in Australia and Brazil both reported 
cow’s milk allergy in EoE patients (27% of cases and 22.8% of cases, respectively) (Philpott, Nandurkar, 
Royce, Thien, & Gibson, 2016; Rodrigues Mariano De Almeida Rezende et al., 2014) (Table 4). In the 
United States, a study in Illinois reported the most common food allergen as soy (38.89% of all cases), 
whereas studies centered in Ohio, Wisconsin, and New York had higher rates of nut allergies (40.9% of 
cases, 51%, and 50% of cases, respectfully) (Fahey et al., 2017; Kagalwalla et al., 2017; Slack et al., 
2013) (Table 4). New York also examined aeroallergen sensitization associated with EoE, where <20% of 
records had sensitization to grasses, dust mites, or animal dander. Investigators in Wisconsin identified 
native trees (70%) as the dominant aeroallergen (Fahey et al., 2017; Xiwei Zheng, Cong Bi, Marissa 
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Brooks, 2015) (Table 4). Finally, Spain reported that individuals with EoE experienced heightened 
sensitization to rye (36.4% of patients) and Bermuda grasses (27.1% of cases) (Armentia et al., 2018) 
(Table 4). 
 
Table 4. EoE Sensitization Patterns in the Literature. 
Reference 
(year) 
Olson 
(2016) 
Kagalwalla 
(2016) 
Slack 
(2016) 
Fahey 
(2017) 
Armentia 
(2017) 
Rodrigues 
(2014) 
Philpot 
(2016) 
Location WI* IL* OH* NY* Spain Brazil Aust 
Population n = 257 n = 78 n = 66 n = 38 n = 129 n = 35 n = 75 
Aeroallergens 
Weed 40.0% ** 66.6% ** ** ** ** 
Grass1 55.0% ** 62.1% 17.0% 63.5% ** 70.0% 
Tree2 70.0% ** 59.1% 14.0% 9.3% ** 2.00% 
Dust mites 69.0% ** 50.0% 17.0% 71.4% ** 67.0% 
Mold 46.0% ** 39.4% 00.0% ** ** ** 
Dander3 66.0% ** 39.4% 23.0% ** ** ** 
Food Allergens 
Cow milk 25.0% 23.6% ** 31.0% ** 22.8% 27.0% 
Egg white 21.0% 33.3% ** 39.0% ** 8.50% 4.00% 
Soy 35.0% 38.9% ** 28.0% ** 22.8% 10.0% 
Meat4 ** ** ** 11.0% ** 34.1% ** 
Seafood ** ** ** 14.0% ** 14.2% 0.00% 
Wheat 17.0% 20.8% ** 33.0% ** 2.80% 19.0% 
Nuts5 51.0% ** ** 50.0% 9.3% ** 4.00% 
Food6 ** ** ** 39.0% ** ** ** 
*United States reports 
**Allergen not tested 
1Grass (other) –Bermuda grass and/or rye grass  
2Tree (other) – each and/or olive 
3Dander – cat and/or dog and/or bird 
4Meat –chicken and/or pork and/or beef 
5Nuts –peanuts and/or walnuts and/or 
hazelnuts  
6Food (other) –vegetables and/or fruits 
  
  
The goal of this study was two-fold. First, atopic comorbidities and sequela of EoE in Nevada 
were examined by means of a hospital utilization database and the most common comorbidities identified 
in the state across both pediatric and adult eosinophilic esophagitis patients. Second, this study aimed to 
demonstrate if Nevada has unique allergen sensitization patterns given the state’s extreme climate and 
health care challenges utilizing an allergy referral clinical dataset for histologically positive EoE pediatric 
patients. It is hypothesized that statewide, Nevada EoE patients have distinct differences in comorbid 
conditions as compared to EoE patients in other US geographic locations.    
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Methods 
 Records were extracted and filtered to include only Nevada residents. Inclusion criteria for this 
study included healthcare records with primary (1) through quaternary (4) EoE diagnosis codes (ICD-9 = 
530.13 or ICD-10 = K20.0) from all hospital settings, resulting in a total of 2,298 records. Only primary 
through quaternary diagnosis code records were considered “relevant”  to the study, as EoE can also be a 
comorbidity (Durrani et al., 2018). Each data point represents a hospital record and not an individual 
patient in this database. Exclusion criteria included records that did not contain an EoE ICD-9 or ICD-10 
code in the primary through quaternary diagnosis codes and patients that lived outside the Nevada state 
line.  
 Furthermore, permission was granted by the University of Nevada, Reno School of Medicine 
(UNR SOM) to use a pediatric allergy/immunology clinical skin test dataset. Then derived from pediatric 
gastroenterologist referrals to the UNR SOM Allergy Clinic patients less than 18 years of age who had 
biopsy proven EoE. The clinical presentation of the patients was known and documented in the dataset. 
Skin testing methods were derived from Wong et al. (2012) and were performed with glycerinated 
extracts purchased from ALK-Abello (Denmark, EU).  Percutaneous skin test utilizing a DermaPik were 
performed, a positive control of histamine and negative saline control were placed (Corder & Wilson, 
1995).  Histamine results of 3 mm or larger were considered an adequate positive control (Wong et al., 
2012).  Sensitization was noted with either an aeroallergen or food extract if reaction was at least ½ the 
size of the measured histamine and was also larger than then negative control (Wong et al., 2012). This 
project was deemed exempt for secondary data analysis by the UNLV Office of Research Integrity 
Human Subjects Board due to the de-identified nature of the data. 
Statistical Analysis  
 Descriptive statistics were performed to identify demographics most associated with EoE records 
across various characteristics. The results were presented by demographic of interest (all pediatric records 
versus all adult records and all male records versus all female records). All variables were categorical 
(race, gender, and all-cause diagnosis levels 1 through 4), including age which was grouped into pediatric 
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(0-17 years) and adult (18+years) subgroups.  Using diagnosis variables “diag 01 – diag 04”, 
comorbidities were extracted from and ranked from highest to lowest in occurrence by age and gender. 
This allowed for the identification of comorbidities for stratification. Due to numerous and duplicate ICD-
9 and ICD-10 codes, similar clinical conditions and codes were grouped together for ease of ranking the 
comorbidities. Gastritis codes were reduced to include only specified, post-biopsy ICD codes to prevent 
over representation of a common “catch-all” clinical code. Lastly, frequencies were calculated for the 
clinical sensitization data provided by the UNR SOM to determine which food allergens or aero allergens 
were most prevalent.  
Results 
Population 
 The initial CHIA database search yielded over 12 million all-cause hospital utilization records 
over five years (2013-2017) for the state of Nevada. Data reduction resulted in removal of one repeat 
record and one additional record from the database as the zip-code listed indicated a potential data entry 
error. The final count after data reduction was 2,196 EoE records across all study years (2013-2017) and 
hospital settings. A clinical subset obtained from UNR SOM included 59 cases of histologically 
confirmed pediatric EoE patients from both Reno and Las Vegas, Nevada and yielded sensitization results 
for >100 potential food and aeroallergens. 
Nevada Demographic Results 
 The mean age of the pediatric population was 10.0 years (median = 11 years, standard error of the 
mean (SE) = 0.175); the adult population the mean age was 46.2 (median = 45 years, SE = 0.416) (Table 
5). Mean age among female EoE patients was 39.2 (median = 40.5 years, SE = 0.747), and males was 
29.8 (median = 27 years, SE = 0.565) (Table 5). Caucasian was the predominant race among all EoE 
records and Native American/Alaskan was the least represented (<1.0% of the dataset) (Table 5). There 
was less male representation among the pediatric than the adult records; male n = 594 (27.05%) and n = 
804 (36.61%), respectively (Table 5).  
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Table 5. Demographic Analysis Among All Positive EoE Records in Nevada. 
 
Pediatric (0-17) 
n = 785 
Adult (18+) 
n = 1,411 
Female 
n = 798 
Male 
n = 1,398 
Age (mean/SE*) 10 (0.18) 46.2 (0.42) 39.2 (0.75) 29.8 (0.57) 
Race n (%) n (%) n (%) n (%) 
White/Caucasian 526 (23.9%) 834 (37.9%) 504 (63.2%) 856 (61.2%) 
Asian/Pacific Islander 22 (1.00%) 28 (1.28%) 14 (1.75%) 36 (2.58%) 
Black/African American 66 (3.01%) 33 (1.50%) 24 (3.00%) 75 (5.36%) 
Hispanic 66 (3.01%) 58 (2.64%) 40 (5.01%) 84 (6.00%) 
Native American/Alaskan 1 (0.05%) 2 (0.09%) 1 (0.12%) 2 (0.14%) 
Other 43 (1.96%) 21 (0.96%) 13 (1.63%) 51 (3.65%) 
Unknown/Missing 61 (2.78%) 435 (19.8%) 202 (25.3%) 294 (21.4%) 
Gender                 Female 191 (8.70%) 607 (27.6%)   
Male 594 (27.1%) 804 (36.6%)   
*Standard Error (SE)     
 
 
Comorbidities Associated with EoE in Nevada  
 In a thorough literature review, EoE was commonly diagnosed along with atopic diseases, 
therefore, atopic comorbidities were extracted from published literature. Common published EoE 
comorbidities are presented in Table 6. While not directly comparable to the results table, it should be 
noted that the CHIA dataset listed asthma as a comorbidity in 11.2% of EoE records, followed by food 
allergies (2.19%), and atopic dermatitis/eczema (1.55%). Allergic rhinitis and allergic conjunctivitis were 
listed as comorbidities in <1.0% of records.  While not directly comparable to the published literature, it 
appears that the atopic comorbidities from positive EoE patient records in Nevada was far lower than 
many other allergy referral clinic studies performed in the United States and abroad.  
Table 6. Summary of the Most Reported Atopic Disease Comorbidities Associated with EoE Nationally 
and Abroad. 
Ref. Sugnanam 2017 
Rodrigues 
2014 
Moawad 
2010 
Mansoor 
2016 
Fahey 
2017 
Kagalwalla 
2017 
Mohammad 
2017 
Letner 
2017 
Loc. Aust. Brazil MD* OH* NY* IL* OH* MA* 
Asthma 66.7% 60.0% 11.0% 29.2% ** 28.2% 39.0% 45.0% 
Food ** ** 13.4% 20.3% ** 31.1% ** 57.9% 
AD1 55.6% 42.8% 6.29% 26.3% ** 41.0% 46.1% 27.4% 
AR2 93.3% 74.2% 33.9% 35.1% 36.0% 58.9% 61.9% 70.0% 
AC3 ** ** ** ** ** 17.9% ** ** 
*United States reports 
**Comorbidity not reported 
1Atopic Dermatitis/eczema  
2Allergic Rhinitis 
3Allergic Conjunctivitis 
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 Esophageal obstructions and esophageal strictures/stenoses ranked highest among the adult, male, 
and female demographic groups in Nevada (23.87%, 13.16%, and 16.45%, respectively) (Table 7). Hiatal 
hernias were also present, at 10.1% in the adult, 7.52% in the female, and 6.22% in the male subgroups 
(Table 7).  A common comorbidity in males included asthma (7.87%). Other comorbidities were similar 
among the female and male demographic subgroups and included diseases of the stomach, duodenum, 
and intestine (8.15% and 11.9%, respectively), atrophic gastritis (4.26% and 4.8% (not shown), 
respectively), and gastroesophageal reflux diseases (5.51% and 8.66%, respectively) (Table 7).  The top 
comorbidity for pediatric records was asthma (13.4%), followed closely by diseases of the stomach, 
duodenum, and intestine (7.26%) (Table 4). Various food allergies (7.01%) were the third most common 
comorbidity listed. Pediatric patients also exhibited diseases of the stomach, duodenum and intestine, 
hiatal hernia, atrophic gastritis, and GERD (Table 7).  
 
Table 7. Comorbid Conditions and Sequela of EoE by Age and Gender. 
Comorbidity n (%) 
Female EoE Positive Records 
Esophageal obstruction, Stricture/stenosis of esophagus 150 (18.8%) 
Diseases of the Stomach, duodenum, intestine 65 (8.15%) 
 Hiatal Hernia 60 (7.52%) 
Gastroesophageal Reflux Disease (or related) 44 (5.51%) 
Atrophic Gastritis 34 (4.26%) 
Male EoE Positive Records 
Esophageal obstruction, Stricture/stenosis of esophagus 277 (19.8%) 
Diseases of the Stomach, duodenum, intestine 166 (11.9%) 
Gastroesophageal Reflux Disease (or related) 121 (8.66%) 
Asthma 110 (7.87%) 
Hiatal Hernia 84 (6.22%) 
Adult (18+) EoE Positive Records 
Esophageal obstruction, Stricture/stenosis of esophagus 416 (29.5%) 
Diseases of the Stomach, duodenum, intestine 163 (11.5%) 
Gastroesophageal Reflux Disease (or related) 149 (10.6%) 
Hiatal Hernia 142 (10.1%) 
Atrophic Gastritis 48 (3.40%) 
Pediatrics (0-17) EoE Positive Records 
Asthma 105 (13.4%) 
Diseases of the Stomach, duodenum, intestine 57 (7.26%) 
Listed Allergies 55 (7.01%) 
Atrophic Gastritis 40 (5.10%) 
Gastroesophageal Reflux Disease (or related) 29 (3.69%) 
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Clinical Allergy Sensitization Data 
 The clinical subset contained pollen and food sensitization results from EoE patients in one clinic 
located within the University of Nevada, Reno School of Medicine. Overall, 49 foods and 51 
aeroallergens were tested for 59 pediatric patients. In total, 76.3% of patients demonstrated food allergy 
sensitization to at least one food.  Of EoE patients with food allergy sensitization the food group with the 
highest rate of sensitization was nut and seed (n = 34, 57.63%); followed by dairy (n = 23, 38.98%), 
seafood (n = 23, 38.98%), vegetables (n = 18, 30.51%), and grains (n = 13, 22.03%) (Table 8). Nearly 
95% of patients demonstrated aeroallergen sensitization. Over 80% of the positive EoE pediatric patients 
had sensitization to weed pollen (n = 50, 84.75%) and tree pollen (n = 49, 83.05%); over 70% to grass 
pollen (n = 45, 76.27%), and animal dander (n = 43, 72.88%) (Table 5). Overall, aeroallergen 
sensitization from weed and tree were >20% higher in pediatric patients than the highest observed food 
allergen nuts/seeds (n = 34, 57.63%) (Table 8). Skin prick results from all 59 patients are presented below 
(Table 8). Overall, among the 59 pediatric patients tested there were 1,495 total positive reactions 
between food allergens and aeroallergens. Only 17.06% (n = 255) of the positive reactions were from 
food allergens and 82.94% (n = 1,240) of the positive reactions were from the aeroallergens tested.  
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Table 8. Sensitization Results from Histologically Positive EoE Pediatric Patient Skin Prick Tests. 
Food Allergens (n (%)) Aeroallergens (n (%)) 
Nuts/Seeds1 34 57.63% Weed9 50 84.75% 
Dairy2 23 38.98% Tree10 49 83.05% 
Seafood3 23 38.98% Grass11 45 76.27% 
Vegetables4 18 30.51% Dander12 43 72.88% 
Grains5 13 22.03% Mold13 15 25.42% 
Meat6 12 20.33%    
Seasonings7 11 18.64%    
Fruit8 7 11.86%    
All Allergens (n = 1,495 total + reactions) 
Food Positive 255 17.06% 
Aero- Positive 1,240 82.94% 
1Nuts/Seeds – peanut, cashew, almond, walnut, pecan, hazelnut, pistachio, Brazil nut, coconut, sunflower 
seed, sesame seed 
2Dairy – egg, milk, soy 
3Seafood – cod, oyster, shrimp, crab, flounder, tuna, lobster, clam, salmon, scallops 
4Vegetables – celery, garlic, onion, pea, tomato, carrot, corn, white potato, sweet potato 
5Grains – wheat, barley, oat, rice 
6Meat – beef, chicken, lamb, pork, turkey 
7Seasonings – vanilla, cinnamon, mustard, cocoa 
8Fruit – avocado, orange, apple, strawberry, blueberry, banana, pear, peach, apricot, pineapple, cantaloupe 
9Weed: pigweed, sagebrush, plantain, dock, ragweed, ragweed-mix, marsh elder, Russian thistle, rabbit bush, 
saltbush 
10Tree (other) – pecan, juniper, cedar, alder, oak, elm, willow, locust, cottonwood, birch, maple, privet, aspen, 
olive, sycamore, pine, walnut, sweet gum, mulberry, ash, ailanthus 
11Grass (other) – timothy, brome, bermuda, saltgrass, johnson, alfalfa 
12Dander – horse, hamster, feather, cat, dog, cattle, mouse, cockroach 
13Mold – Alternaria, Aspergillum, Penicillium, Cladosporium, Drechslera, Curvularia, moldmix2, Smuts 
(Reported as percentage of total cases with at least one positive result; n = 59). 
 
 
Discussion 
 Eosinophilic esophagitis studies in the state of Nevada are limited.  There are several published 
studies nationally and internationally; yet this is the first study to our knowledge examining EoE 
comorbidities in the state of Nevada. The results for this study are novel as the reported comorbidities and 
allergens are significantly different than those reported in the literature. Pediatric allergy sensitization data 
suggest that those with atopic comorbidities may have more aeroallergen induced disease than food 
allergy associated disease than previously reported.  
 Over 30% of the CHIA adult EoE population had reported esophageal obstruction, stenosis, or 
stricture of the esophagus. These results indicate that EoE patients in Nevada are seen in the later stages 
of the illness where cost is high and when damage is potentially irreparable. A study in 2016 examined a 
cohort EoE positive patients and identified that delay in EoE diagnosis was associated with stricture 
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formation (Lipka, Kumar, & Richter, 2016). A significant difference in mean time of diagnosis was 
observed in positive EoE patients with less than 10mm esophageal diameter when compared to patients 
with a diameter greater than 10mm (Lipka et al., 2016).   In another study, esophageal function tests were 
examined and researchers concluded that function of the lower esophageal sphincter and muscles of the 
esophagus decrease with longer EoE disease duration (van Rhijn, Oors, Smout, & Bredenoord, 2014). 
This study reports that the longer the disease duration, the prevalence of abnormal esophageal functioning 
increases from 36% in those with a disease duration between 0-5 years to 83% in those with disease 
duration over 16 years (van Rhijn et al., 2014). Additionally, routine EoE visits, as reported in a study by 
Jensen et al. (2015), determined that patients with EoE cost over $3,000 per visit compared to $1,000 for 
gender and age matched controls at the same hospital (p<0.001) (Jensen et al., 2015). According to the 
study, a significant amount of the cost increase was due to the increased number of endoscopies and 
pharmacy claims, particularly once EoE progressed to later stages as seen in the Nevada population 
(Jensen et al., 2015). 
  Over 10% of all adult EoE records in Nevada listed hiatal hernia as comorbid. Both Barrett’s 
esophagus, a serious complication of GERD, and hiatal hernias have been loosely associated with EoE in 
several studies (AJ., 1995; Cherian, Smith, & Forbes, 2006; Maradey-Romero, Prakash, Lewis, 
Perzynski, & Fass, 2015; Schoepfer et al., 2013; Takashima S, Tanaka F, Otani K, Hosomi S, Nagami Y, 
Kamata N, Taira K, Yamagami H, Tanigawa T, Fukumoto S, Watanabe T, 2019).  One study from 
Minnesota highlighted that hiatal hernias likely contribute to the development of  Barrett’s esophagus 
(AJ., 1995). A 2019 study from Japan argued that while Barrett’s esophagus was negatively associated 
with EoE, hiatal hernias were observed in over 20% of the EoE population (Takashima S, Tanaka F, 
Otani K, Hosomi S, Nagami Y, Kamata N, Taira K, Yamagami H, Tanigawa T, Fukumoto S, Watanabe 
T, 2019). Based on published literature, an association between EoE, hiatal hernia, and Barrett’s 
esophagus may exist, particularly in the Nevadan population where Barrett’s esophagus codes were 
observed among 2.09% (n = 46) of positive EoE records. 
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 The only atopic comorbidities present in the CHIA dataset appeared in the male and pediatric 
subgroups. In males, asthma was reported in nearly 8.0% and approximately 13% in pediatrics, lower 
than reported state averages (10.4% in adults and 23.0% in pediatrics). Australia, Brazil, and Ohio both 
report high asthma rates among EoE patients (Mohammad et al., 2017; Rodrigues Mariano De Almeida 
Rezende et al., 2014; Sugnanam et al., 2007). When the diagnosis code search was expanded (diagnosis 
position 05 – 37), allergic rhinitis was observed in <1% of the EoE population in Nevada (n = 2,196). In 
Australia, EoE is often seen in conjunction with allergic rhinitis (93.33% of patients), followed by 
asthma, atopic eczema, and anaphylaxis (Sugnanam et al., 2007). Brazil reports allergic rhinitis as the 
most common comorbidity, identified in 74.2% of EoE cases, with asthma and atopic dermatitis 
following closely behind (Rodrigues Mariano De Almeida Rezende et al., 2014).  In the United States, 
Massachusetts, Ohio, and New York all reported allergic rhinitis as the most common comorbidity (70%, 
61.9%, and 36%, respectively), followed by food allergies, asthma, and atopic dermatitis (Fahey et al., 
2017; Letner et al., 2018; Mohammad et al., 2017). Illinois also specified allergic rhinitis as the most 
common comorbidity among EoE patients (58.9% of cases), followed by eczema, food allergies, asthma, 
and allergic conjunctivitis (Kagalwalla et al., 2017).  Compared with the published literature worldwide, 
the atopic comorbidities identified in Nevada EoE records were much lower than expected.  
Clinical Subset 
 The clinical subset highlighted several notable distinct allergens not found in other regions. In 
three of the largest EoE population studies, authors claim that food allergies were the causative agent of 
the disease in over 90% of patients (Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, 1995; 
Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E, Flick J, Kelly J, Brown-
Whitehorn T, Mamula P, Markowitz JE.Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas 
M, Semeao E, Flick J, Kelly J, Brown-Whitehorn T, Mamula P, 2005; Markowitz JE, Spergel JM, 
Ruchelli E, 2003). In the clinical subset of Nevada patients, weed, tree, and grass sensitization were 
dominantly identified. Overall, positive skin prick tests for food allergens accounted for 17.06% of the 
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total positive skin test results whereas positive aeroallergen results were found in over 80% of the 
pediatric EoE patients.  
 Within the food sensitized patient population the percent of these patients having specific food 
group positive skin test results were similar to or lower, than other published studies. The highest food 
allergen group identified in Nevada among positive EoE patients was nuts/seeds (57.63%). Other studies 
report nut allergens in EoE patients between 4% (Australia) and 51% (Wisconsin, USA) (Philpott et al., 
2016; Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). Dairy (38.98%) and seafood (38.98%) were among 
the other food allergens identified in Nevada. In other studies, dairy ranges from 4.00% (Australia) and 
39.0% (New York, USA) and seafood ranges from 0.00% (Australia) to only 14.0% (New York, USA) in 
EoE patients (Fahey et al., 2017; Philpott et al., 2016). 
 Weed sensitization in Nevada is reported in nearly 85% of EoE patients. The highest identified 
weed allergens in the literature exist in Wisconsin and Ohio, where weed allergens are only identified in 
40% and 60% of cases, respectively (Slack et al., 2013; Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). 
Tree pollen sensitization are found in 83% of EoE patients in our Nevada clinical subset. In the literature, 
tree pollen allergens in the EoE population range from 2.0% in Australia to 70% in Wisconsin (Philpott et 
al., 2016; Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). Grass sensitization in Nevada were identified in 
over 75% of the pediatric patients tested; grass sensitization is reported in 17.0% of individuals diagnosed 
with EoE in New York, and close to 70% of EoE patients in Australia (Fahey et al., 2017; Philpott et al., 
2016). Animal dander was reported in 72.88% of the EoE Nevadan population, but in only 66.0% in 
Wisconsin, 39.4% in Ohio, and 23.0% in New York (Fahey et al., 2017; Slack et al., 2013; Xiwei Zheng, 
Cong Bi, Marissa Brooks, 2015). Globally, the percent of patients demonstrating aeroallergen 
sensitization from Nevada are significantly higher than other reported studies.  This suggests that a 
geographic etiology may play a role in our findings as most comparable studies are based in the eastern 
segment of the United States. 
 There are several unique geographical factors in Nevada that can explain the significant increase 
in aeroallergen sensitization seen in the pediatric EoE population. In a study examining a cohort of 
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children, Wong et al. (2012) identified that over 50% of children aged between 6-7 were sensitized to at 
least one aeroallergen in the state of Nevada (Wong et al., 2012).  Due to the decreased rain and increased 
wind in the area known as the Great Basin, aeroallergens have significantly increased over the years 
(Wong et al., 2012).  Another study reported that winds across the Great Basin cause pollen variation 
within individual cities in Nevada. Patel et al. (2018) found that variation in pollen concentration occurred 
in microenvironments across five different locations in the city of Las Vegas alone (Patel et al., 2018). 
The study also found significant variations in pollen concentrations and compositions across the city 
(Patel et al., 2018). Tree was the greatest contributor to the average pollen concentrations, followed by 
weed, and grass (Patel et al., 2018). These increased pollen rates may impact pediatric EoE patients more 
than any of the food allergens tested. Nevada gets the least amount of rain annually than any other state in 
the United States. Unlike other states in the Northeastern or Midwestern US, the lack of rain allows for 
the presence of accumulated pollen (Lilly, 2016; Patel et al., 2018). Without rain, pollen accumulates and 
becomes a perennial exposure, which has been previously reported in Nevada (Wong et al., 2012). The 
climate in Nevada could account for the significant differences in allergens observed in this EoE 
population, particularly when compared to the Midwestern and Eastern seaboard regions of the United 
States; where rain and snow are plentiful year-round.  
Strengths and Limitations 
 One limitation for this study includes the inability to calculate true patient level comorbidities; as 
the individual level for analyses is the patient record and not the individual. This is particularly true for 
the esophageal obstruction, stricture, and stenosis ICD code used. Some records are likely repeat visits, as 
patients with EoE tend to be seen multiple times per year due to strictures or stenoses. Repeat visits 
cannot be accounted for in the data making it difficult to determine how many individual patients are truly 
represented within the dataset. Finally, there are less than 30 allergists listed on the American Academy of 
Allergy, Asthma, & Immunology (AAAAI) website for the state of Nevada; this indicates that there are 
not enough specialty allergists in the state making EoE difficult to capture or diagnose which may be 
contributing to the inconsistency in treatment by provider and region. 
35 
 
 A major strength of this study is the large population size of EoE records gathered from the CHIA 
database across multiple years; as well as the large number of conditions identified with diagnosis codes. 
Study power was sufficient to assess a condition that may otherwise have been difficult to achieve an 
adequate sample size. As these are healthcare utilization data with diagnosis codes, these data are 
typically more accurate than the self-reported data found in some other studies. Additionally, the clinical 
subset provided by UNR SOM allowed for a clinical and parallel assessment among a unique population. 
This data shows a significant burden of disease for EoE patients overall. This clinical dataset was referred 
by a GI subspecialist to an allergy subspecialist, making it very unique.  
Conclusion 
 While the scientific knowledge of EoE continues to grow, more studies are required across larger 
geographic regions. Our clinical allergy sensitization dataset indicated that sensitization to aeroallergens 
in EoE patients far exceed the presence of food sensitization. These patterns conflict with most studies, 
making this novel information for providers of EoE patients, especially in climates like Nevada.  
 In Nevada irreversible sequela, obstructions/stenosis/strictures were seen in 30% of adult patients 
and less than 1% of pediatric patients had this, none of which were part of our clinical subset. High rates 
in adults have been shown to be due to delayed diagnosis. Low rates in children may be due to early 
diagnosis of these patients by allergists and pediatric gastroenterologists in Nevada. Furthermore, 
adequate care for pediatrics through the use of both GI and allergy specialists may help prevent disease 
progression. Both of which suspect the disease and may understand the importance of aeroallergen 
importance. However, in the adult population this may not be the case. Given the large number of patients 
with aeroallergen sensitizations from the referral clinical database, we suspect that this comorbidity is 
being under diagnosed state wide. More literature in similar climates with evidence similar to our 
experience may increase awareness of these being comorbid conditions and lead to earlier diagnosis and 
result in less severe sequela of the disease.  
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Chapter 4: Impact of Eosinophilic Esophagitis in Nevada 
 
Abstract 
 The cost and quality of life impact of the rare disease eosinophilic esophagitis (EoE) are seldom 
discussed in the literature. This study examines the cost of EoE in the state of Nevada and puts into 
context the severity of the illness when compared to similar, more well-known chronic immune 
inflammatory conditions. Several significant demographic factors influenced the overall cost of EoE in 
Nevada, including those in the pediatric age group, males, and those living in the Southern region 
(p<0.001). Using Mann Whitney U, when cost is compared to Crohn’s disease and Celiac disease, EoE is 
significantly more expensive for pediatric records, those living in the southern region, males, and those 
seeking medical advice from outpatient therapy centers (p<0.001). A binary logistic regression model 
revealed that age, gender, region, and hospital setting were all associated with having a positive EoE 
versus Crohn’s disease record (p<0.001). Additionally, a second model revealed that age, gender, and 
hospital setting were all associated with having a positive EoE record versus a Celiac disease record 
(p<0.001). Here, were present data showing that EoE is as significant as other chronic inflammatory 
illnesses in the state of Nevada. Education for this disease should be drastically improved as the 
prevalence continues to rise.  
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Introduction 
 Eosinophilic esophagitis (EoE) has been described worldwide since before 1980, however, this 
disease was only recently identified by the United States International Classification of Diseases (ICD) in 
1998 (James & Assa’ad, 2018).  According to the American Partnership for Eosinophilic Disorders 
(APFED), coding for EoE had previously relied on specific symptomology for already known conditions, 
including: dysphagia, achalasia, and gastroesophageal reflux disease (GERD) (James & Assa’ad, 2018). 
While this disease is now more recognizable, concern in gastroenterology, allergy, and immunology 
communities continues to grow as new information surfaces (James & Assa’ad, 2018).  With this disease 
on the rise alongside atopic diseases, few studies examine the overall cost of this EoE, particularly in 
comparison to similar chronic immune or inflammatory conditions (Davis, 2018).   
 Jensen et al. (2015), to our knowledge, is the only published study that has attempted to estimate 
the cost of EoE in the United States (Jensen et al., 2015). This study examined US claims data and 
identified 8,135 cases of EoE (Jensen et al., 2015). In a matched study with 32,540 controls for 
comparison, Jensen et al. calculated the median annual cost per EoE record at $3,304.00; triple the total 
cost of $1,001.00 calculated per gender and age matched controls (p < 0.001) (Jensen et al., 2015). Costs 
included additional outpatient visits, endoscopies, and pharmacy claims, all related to an EoE diagnosis 
(Jensen et al., 2015).  Jensen et al. (2015) estimated the overall annual cost of EoE in the United States as 
upwards of $1.4 billion, which is an astounding overall cost for a disease that was formally classified just 
over two decades ago (Jensen et al., 2015).  The study gave a broad overview of EoE cost in the United 
States; however, did not provide a differentiation of cost by demographic subgroup or provide context to 
the overall cost exhibited by the illness. 
 Economic burden is difficult to conceptualize for a rare disease like EoE. This study sought to 
add to the current literature by examining the overall cost of EoE by demographic subgroup in the state of 
Nevada using a large hospital utilization database. By examining the cost associated with age, gender, 
region, and hospital setting, this study aimed to describe the significant differences in treatment cost and 
options utilized in the state by demographic.  Additionally, the overall cost of EoE records was compared 
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with two similar and well-categorized chronic inflammatory diseases, Crohn’s disease (CD) and Celiac 
disease (CeD), to illustrate the relative cost burden of EoE in Nevada. Logistic regression models were 
utilized to identify key factors that set EoE apart from CD and CeD to stress that EoE, while considered 
rare, is just as costly and dangerous.  
Methods 
Population 
 Records from the database were extracted and filtered to include only Nevada residents. Inclusion 
criteria for this study included healthcare records with primary (1) through quaternary (4) EoE diagnosis 
codes (ICD-9 = 530.13 or ICD-10 = K20.0) from all hospital settings. Exclusion criteria included the 
presence of a concurrent or comorbid CD or CeD ICD codes with EoE, resulting in a total of 2,190 
positive EoE records across all study years (2013-2017) and hospital settings. It should be noted that 
record was the individual level of analyses and not the actual patient.   
 Several factors were involved with the selection of the comparator illnesses, CD and CeD, for the 
cost comparison. First, the relationship between EoE and atopic diseases is well documented in the 
literature, therefore an allergic component was included (Benninger, Strohl, Holy, Hanick, & Bryson, 
2017). Secondly, the diseases were to be clinically similar as well as require equivalent diagnostic 
methods. All three diseases presented here are chronic immune mediated illnesses with documented 
relationships to atopy (Benninger et al., 2017; Katsanos, Zinovieva, Lambri, & Tsianos, 2011; Leslie, 
Mews, Charles, & Ravikumara, 2010; Stewart, Shaffer, Urbanski, Beck, & Storr, 2013).  Specifically, 
Eosinophilic esophagitis is an immune-mediated disease characterized by esophageal or upper 
gastrointestinal symptomology, diagnosed via endoscopy and pathological findings, and treated using 
dietary restrictions or high-dose proton pump inhibitors (Leslie et al., 2010). Celiac disease is an immune-
mediated illness characterized by intolerance or allergy to dietary gluten causing significant damage to the 
intestine, and treated using dietary restrictions or anti-inflammatory medication (Leslie et al., 2010; 
Stewart et al., 2013). Crohn’s disease is an inflammatory bowel disease diagnosed via colonoscopy and 
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treated short-term using corticosteroids or immune system suppressors and long-term using dietary 
restrictions (Katsanos et al., 2011). 
Statistical Analysis 
 The total associated service costs for EoE were extracted and analyzed by demographic subgroup: 
age (pediatric (0-17) versus adult (18+)), gender (male versus female), and region (North versus South). 
Once extracted, the median cost per demographic subgroup was assessed.  Due to the non-normal 
distribution, the Mann Whitney U test was performed to identify significance in cost within subgroups. 
All demographic subgroups with EoE records demonstrated significant differences (p < 0.05). Therefore, 
frequencies of the top ten most prevalent CPT codes recorded were extracted from the database and 
compared to identify which ICD codes contributed to the differences in cost. 
 Positive EoE records were then compared to two additional chronic inflammatory diseases. In 
order to compare the cost of EoE to clinically well-categorized chronic inflammatory illnesses, a random 
matched selection of 2,190 records of CD (ICD-9 = 555.9, 560.89 or ICD-10 = 50.00) and CeD (ICD-9 = 
579.0 or ICD-10 = K90.0) were extracted from the hospital utilization database across the same 
timeframe. Due to a small number of extreme outliers, records >99th percentile were removed before the 
final analysis, resulting in EoE (n = 2,167), CD (n = 2,168), and CeD (n = 2,168) total records. 
Frequencies were calculated for demographic and median cost for each disease, as well as Mann Whitney 
U to identify significant differences in cost by demographic subgroup.  
 Binary logistic regression models were run to determine if demographics were impacted more 
significantly by EoE than CD or CeD. Secondary analysis was performed to identify demographic 
differences between the diseases of interest in terms of odds ratios. The dependent variable was an EoE 
positive record (1) versus a positive CD or CeD record (0). A P-value of less than 0.05 and the 95% CI 
were set for statistical significance for all binary logistic regression models. All statistical analyses were 
run using R version 3.1.5 (11). 
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Results 
Nevada EoE Cost Burden 
 
 Overall, the cost of EoE in Nevada varied significantly by demographic factors. The median cost 
per record for adults ($1,906.00) on average, was less compared with pediatric records ($4,001.00) (p < 
0.001) (Table 1).  The median cost per male record ($2,532.5) was greater than females ($1,906.00) 
(Table 1).  Finally, records extracted from the Southern region yielded a median cost of $4,501.00 
compared with $1,025.00 per record for the Northern region of the state (p < 0.001) (Table 9).  
 To identify why the significant differences in cost existed by demographics, CPT codes were 
extracted from all positive EoE records and compared by subgroup. The most prevalent CPT code among 
all EoE records included esophagogastroduodenoscopy (by age, region, and gender) (Table 9). Among 
adults and females, miscellaneous surgical supplies (n = 269, 19.1%; n = 124, 15.7%, respectively), 
fentanyl citrate 0.1mg injections (n = 229, 16.3%; n = 120, 15.2%, respectively), and surgical pathology 
gross and microscopic examination (n = 163, 11.6%; n = 149, 18.8%, respectively) were the most 
prevalent subsequent CPT codes recorded (Table 9). CPT codes identified for the pediatric sub-group 
were as follows: surgical pathology gross and microscopic examination (n = 273, 34.5%) was more 
prevalent, followed by 10mg propofol injections (n = 233, 29.8%) and special stains with interpretation 
and reporting (n = 123, 15.8%) (Table 9). Among male EoE records, the most prevalent reported CPT 
codes included surgical pathology gross and microscopic examination (n = 299, 21.4%), followed by 
10mg propofol injections (n = 229, 16.4%), and miscellaneous surgical supplies (n = 196, 14.02%) (Table 
9). One important difference among EoE records by gender was the presence of the urinalysis procedure 
for females (n = 67, 8.46%) but not males (Table 9).  
 The largest difference in EoE record patterns existed by region of the state. The difference in total 
number of positive EoE records between regions was less than 10%, however, the median cost per record 
in the Southern region was over 50% higher when compared to the Northern region (p < 0.001). In the 
Northern region, miscellaneous surgical supplies (32.3%), fentanyl citrate 0.1mg injections (28.4%), and 
venous procedures (15.5%) were among the most prevalent CPT codes recorded (Table 9). However, 
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miscellaneous surgical supplies and fentanyl citrate 0.1mg injections in the Southern region of the state 
accounted for less than 1%, followed by very low venous procedure rates (3.86%) (Table 9). In the 
Southern region, surgical pathology gross and microscopic examination (34.3%), 10mg propofol 
injections (25.0%), and special stains with interpretation and reporting (16.0%) comprised the majority of 
the CPT codes when compared to the Northern region (Table 9).  
 
Table 9. CPT Codes and Associated Cost Among Positive EoE Records. 
Demographic n % Total Cost Median Cost Cost/Record P-value* 
Pediatric (<18 yrs.) 781 35.7% $3,728,583 $4,001.00 $4,774.11 <0.001 
Adult (+18 yrs.) 1409 64.3% $5,047,355 $1,906.00 $3,582.22  
Female 792 36.1% $2,852,379 $1,906.00 $3,601.49 0.0012 
Male 1398 63.8% $5,923,559 $2,532.50 $4,237.17  
North 999 45.6% $1,594,792 $1,025.00 $1,596.39  
South 1191 54.4% $7,181,146 $4,501.00 $6,029.51 <0.001 
CPT Codes by Demographic in Nevada (n %) 
 Adult Pediatric Male Female North South 
Esophagogastroduodenoscopy 
  
915 
64.9% 
288 
33.0% 
746 
53.4% 
424 
53.5% 
734 
73.5% 
438 
36.8% 
Surgical supply miscellaneous 
  
 
269 
19.1% 
61  
6.53% 
196 
14.02% 
124 
15.7% 
323 
32.3% 
<1.00% 
Injection, fentanyl citrate,  
0.1 mg 
229 
16.3% 
61  
7.81% 
175 
12.5% 
120 
15.2% 
284 
28.4% <1.00% 
Surgical path, gross and  
microscopic examination 
163 
11.6% 
273 
34.9% 
299 
21.4% 
149 
18.8% 
30  
3.00% 
409 
34.3% 
Venous Procedures  
 
 
154 
10.9% 
43  
5.51% 
119 
8.51% 
83  
10.5% 
155 
15.5% 
46  
3.86% 
Injection, propofol, 10 mg 
  
64  
4.54% 
233 
29.8% 
229 
16.4% 
64  
8.08% <1.00% 
298 
25.0% 
Special stain with 
interpretation and report  
71  
5.04% 
123 
15.8% 
126 
9.01% 
71 
8.96% <1.00% 
191 
16.0% 
Injection, midazolam 
hydrochloride, per 1 mg  
113 
8.02% 
53  
6.79% 
106 
7.58% 
66  
8.33% 
146 
14.6% 
27  
2.27% 
Urinalysis Procedures 
  
 
26 
1.85% 
33  
4.23% 
<1.00% 67  
8.46% 
<1.00% 57  
4.79% 
Unclassified drugs 
 
 
82  
5.82% 
32  
4.10% 
73  
5.22% 
52  
6.57% 
108 
10.8% 
<1.00% 
*P-value based on Two-Tailed Mann Whitney U (alpha set at 0.05) 
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Demographic and Cost Comparison: EoE, Crohn’s disease and Celiac disease  
 
 When comparing cost of records between conditions, several demographic factors were 
significant (p<0.001) for EoE when compared to both CD and CeD; EoE records had a higher 
representation of individuals less than 18 years of age, the male gender, and southern region location 
(p<0.001) (Table 10).  As for hospital setting, the median cost of inpatient and outpatient therapy centers 
was also significant between EoE and CD and EoE and CeD (p<0.001) (Table 10). While EoE cost 
significantly more in outpatient therapy clinics (p<0.001), CD and CeD each cost significantly more than 
EoE in the inpatient (IP) setting (p<0.001) (Table 10). 
 
Table 10. Total CPT Cost by Demographic and Disease Status. 
Demographic 
Crohn’s Disease (1) 
(n = 2,168) 
p-val.8 
EoE (2) 
(n = 2,167) 
p-val.8 
Celiac Disease (3) 
(n = 2,168) 
 n (%) Cost* n (%) Cost* n (%) Cost* 
Age         
Pediatric  101 (4.61) $985 <0.001 781 (35.7) $4,001 <0.001 113 (6.07) $856 
Adult 2089 (95.4) $1,506 0.63 1409 (64.3) $1,906 0.47 2077 (94.8) $1,623 
Region         
Northern 938 (42.8) $845 0.25 999 (42.8) $1,025 0.012 1024 (46.8) $1,014 
Southern 1252 (57.2) $2,538 <0.001 1191 (57.2) $4,501 <0.001 1166 (53.2) $1,888 
Gender         
Female 1275 (58.2) $1,500 0.57 792 (36.2) $1,906 0.01 1304 (59.5) $1,600 
Male 915 (41.8) $1,500 <0.001 1398 (63.8) $2,532 <0.001 886 (40.5) $1,724 
Hospital Setting        
ASC4 792 (36.2) $1,451 0.04 1045 (47.7) $1,508 0.28 1188 (54.2) $1,600 
ED5 634 (28.9) $1,219 0.01 209 (9.54) $1,371 0.04 577 (26.3) $1,262 
IP6 614 (28.0) $10,474 <0.001 122 (5.57) $6,872 <0.001 220 (10.0) $9,570 
THOS7 150 (6.90) $741 <0.001 814 (37.2) $3,298 <0.001 205 (9.40) $1,686 
*Median Cost per record shown rounded to the nearest dollar amount 
1Demographic frequencies of a random sample of Crohn’s disease records from CHIA. 
2Demographic frequencies of a random sample of EoE records from CHIA 
3Demographic frequencies of a random sample of Celiac disease records from CHIA 
4Ambulatory Surgery Centers 
5Emergency Departments 
6Inpatinet Clinics 
7Outpatient therapy centers 
8P-value calculated using Two-sided Mann Whitney U (alpha set at 0.05) 
 
  
In a final adjusted model, factors associated with having a positive EoE versus CD record were 
identified (p < 0.05); younger age (OR = 7.29; 95% CI: 5.73, 9.27; p<0.001), male gender (OR = 1.78, 
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95% CI: 1.47, 2.15; p-value < 0.001), region (South) (OR = 1.87, 95% CI: 1.032, 3.39; p-value = 0.039), 
and outpatient setting (OR = 1.31, 95% CI: 2.89, 4.73, p-value <0.001) (Table 11). Significant 
interactions were found between region * gender as well as region * hospital setting (p<0.001) (Table 11). 
 
Table 11. Factors Associated with a Positive EoE Event versus Crohn’s Disease (CD). 
 Odds 
Ratio 
95% CI  
Demographic Low High p-value 
Age     
Pediatric (<18) 7.29 5.73 9.27 p<0.001 
Adult (18+) * * * * 
Gender     
Female * * * * 
Male 1.78 1.47 2.15 p<0.001 
Region     
North * * * * 
South 1.87 1.03 3.39 0.039 
Hospital Setting 
Inpatient * * * * 
Outpatient 3.69 2.89 4.73 p<0.001 
Interaction     
Region*Gender  1.18 2.13 p<0.001 
Region*HS  1.99 3.89 p<0.001 
*Reference Group 
1HS: Hospital Setting 
R2: 25.26% 
 
  
Differences existed between region and diagnosis (p<0.001). As such stratified models by region 
were performed (Table 12). In the Northern region the following factors had significantly higher odds of 
an EoE event versus a CD event: younger age (OR = 7.17, 95% CI: 4.68, 10.99, p<0.001), male gender 
(OR = 1.78, 95% CI: 1.47, 2.16; p<0.001), and outpatient hospital setting (OR = 3.69, 95% CI: 2.88, 4.72; 
p<0.001) (Table 12).  In the Southern region, the pediatric sub-group had 7.35 times the odds (95% CI: 
5.49, 9.83, p<0.001) of having a positive EoE versus a CD event. Additionally, male records (OR = 2.83, 
95% CI: 2.27, 3.53; p<0.001) as well as those from the outpatient hospital setting (OR = 10.29; 95% CI: 
8.24, 12.87; p<0.001) demonstrated significantly higher odds of an EoE versus a CD event (Table 2).   
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Table 12. Factors Associated with a Positive EoE Event Stratified by Region. 
 Northern Southern 
 OR 95% CI P-value OR 95% CI P-value 
Age       
Pediatric (<18) 7.17 4.68, 10.99 <0.001 7.35 5.49, 9.83 <0.001 
Adult (18+) * * * * * * 
Gender       
Female * * * * * * 
Male 1.78 1.47, 2.16 <0.001 2.83 2.27, 3.53 <0.001 
Hospital Setting       
Inpatient * * * * * * 
Outpatient 3.69 2.88, 4.72 <0.001 10.29 8.24, 12.87 <0.001 
*Reference group 
Adjusted R2 North: 10.52% 
Adjusted R2 South: 36.99% 
 
  
Additionally, a final model was generated in order to determine the odds of having an EoE versus 
CeD code among records. Factors included age, gender, and hospital setting (p<0.001 for all factors). No 
interaction effects were identified in this model (p>0.05) (Table 13). The following factors were 
associated with having a positive EoE versus CeD record: younger age (OR = 8.59, 95% CI: 6.93, 10.7; 
p<0.001), male gender (OR = 2.11, 95% CI: 1.85, 2.42; p-value < 0.001), and records from the outpatient 
setting (OR = 2.91, 95% CI: 2.48, 3.42, p-value <0.001) (Table 13). 
 
Table 13. Factors Associated with a Positive EoE Event versus Celiac disease (CeD). 
 
Odds Ratio 
95% CI  
Demographic Low High p-value 
Age     
Pediatric (<18) 8.59 6.93 10.7 p<0.001 
Adult (18+) * * * * 
Gender     
Female * * * * 
Male 2.11 1.85 2.42 p<0.001 
Hospital Setting 
Inpatient * * * * 
Outpatient 2.91 2.48 3.42 p<0.001 
R2: 16.69% 
 
 
Discussion 
 Patients diagnosed with a rare illness face significant health disparities compared to those with 
well-documented conditions. It can often be difficult for individuals with a rare disease to find reliable 
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information and care for their illness. The data presented here suggest this scenario for EoE patients in the 
state of Nevada.  
 Pediatric EoE records extracted cost significantly more per record (n = 781; $4774.11) that of the 
adult records extracted ($3,582.22) but was 45% smaller in terms of sample size (n = 1,409) (p<0.001). 
There could be several reasons for the significant difference in cost observed. One hypothesis includes the 
high prevalence of atopic illness in children in the state of Nevada (Moawad et al., 2010). Given the close 
relationship of EoE and atopy, the rise in pollen sensitizations in Nevada could be a significant factor for 
the increased cost to treat EoE in this population. Wong et al. identified that among the 2 to 7-year-old 
age group, over 50% of the population observed (n = 123) were sensitized to at least one allergen. A 
second hypothesis is that increased risk is involved in children presenting with EoE and will therefore be 
more costly for parents (Kavitt, Penson, & Vaezi, 2014). Kavitt et al. (2018) performed a cost analysis of 
various EoE treatments on positive EoE patients of all age groups (Kavitt et al., 2014). The study 
proposed that swallowed fluticasone should be used prior to esophageal dilation if the patient continues to 
be symptomatic post proton-pump inhibitor (PPI) therapy (Kavitt et al., 2014). However, among the top 
ten CPT codes extracted from Nevada hospital data, 64.9% of adults and 33.0% of pediatric records 
underwent an endoscopy, but only 5.8% of adult and 4.1% of pediatric records had a code for receiving 
post-surgical medication; indicating that a lack of education may be driving treatment options in Nevada.  
 The difference in median cost per record was also significant by gender (p<0.001). Published 
studies indicate that males are significantly more likely than females to receive an EoE diagnosis, which 
explains the high cost identified in the male records extracted (Dellon, 2014; Dellon & E.S., 2012; 
Dellon, Erichsen, et al., 2015). However, males were far less likely than females to have a urinalysis 
procedure code in their records.  This is an interesting finding and once again points to a lack of 
knowledge regarding EoE in the state of Nevada. While there are several clinical trials seeking enrollment 
for metabolites associated with EoE via urinary analysis, to our knowledge, no such results have been 
published in the literature (Gourley, 2013; The University of Texas Health Science Center Houston, 
2018). 
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 Finally, the total cost per record identified in the Southern region (n = 1,191; $6,029.51) was over 
three and a half times that of the Northern region (n = 999; $1,596.39); even though the sample size of 
records identified only differed by ~10% between regions (p<0.001).  The CPT codes recorded were also 
different by region. For example, records from the Northern region documented far more endoscopies 
performed than the Southern region and therefore reported higher rates of fentanyl citrate, unclassified 
drugs, and miscellaneous surgical supplies. However, in the Southern region, propofol injections were 
much higher, as well as pathology strains, interpretations, & reports, and urinalysis. These results indicate 
that treatments or diagnostic procedures in the Northern and Southern regions of the state differ 
significantly in terms of EoE. This is also reflected in the significant differences in cost exhibited by the 
two regions. While a difference in cost is expected between regions, the total number of EoE records 
extracted from the Southern region of Nevada versus the Northern region does not account for the large 
difference in cost. 
Demographic and Cost Comparison across Conditions in Nevada 
 In an attempt to rank EoE cost burden relative to related but more well-established conditions, 
EoE was compared to CD and CeD. Several demographic factors were significantly different across 
conditions (p<0.001). Additionally, several demographic factors exhibited increased odds of EoE versus 
CD or CeD.  
 It is documented that Crohn’s disease and EoE have several commonalities including the 
epidemiologic trends in Western cultures, potential genetic risk of inheritance, and the use of a 
combination of drug and endoscopic treatments (Molina-Infante, Schoepfer, Lucendo, & Dellon, 2017).  
In this study, the cost of adult records, female records, those from the Northern region, and certain setting 
types was similar between EoE and CD. However, the cost between these two diseases differed 
significantly among records from the pediatric subgroup, those from the Southern region, of male gender, 
and outpatient therapy settings (p<0.001). The pediatric subgroup was less represented in the CD records 
than EoE records; yet the cost for pediatric EoE records was significantly higher per record for EoE than 
for CD (p<0.001). Also in the final model the odds were higher among the pediatric subgroup of having a 
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positive EoE diagnosis versus a positive CD diagnosis. EoE records extracted from the Southern region (n 
= 1191, 57.2%) and those of male gender (n = 1398, 63.8%) showed a similar trend with the median cost 
of EoE records significantly higher than that of CD records (p<0.001). Male records as well as those 
extracted from the Southern region had higher odds of a positive EoE diagnosis than a CD diagnosis. 
Finally, records from a therapy outpatient center setting were more likely to have a positive EoE event 
than a CD event as well as being significantly more expensive (p<0.001). However, records from CD (n = 
614, 28.0%) had a higher representation in the inpatient clinic than EoE (n = 122, 5.57%) and were 
therefore significantly more expensive (p<0.001). Significant differences also existed by region, as shown 
in the stratified interaction model. Significant differences existed between the Northern and Southern 
regions across several demographics. Records that were younger in age, of male gender, and from 
outpatient clinics all had higher odds of a positive EoE event versus a CD event when examined by 
region.  
 The second disease considered relative to EoE was Celiac disease. Several studies indicate that 
EoE and CeD may have an association (Hommeida et al., 2017; Pellicano, De Angelis, Ribaldone, 
Fagoonee, & Astegiano, 2013). The same trend occurred in CeD as did in CD when compared to EoE. 
The median cost for records among adults, from the Northern region, among females, from ambulatory 
surgery centers, and from the emergency department were similar between EoE and CeD (p>0.05). 
However, the median cost among the younger age group, Southern region, males, and outpatient therapy 
centers were significantly more expensive across the EoE records than CeD records. Furthermore, 
significant factors associated with having an EoE event versus a CeD event included: younger age, male 
gender and outpatient hospital setting (p<0.001). It should also be noted that records from CeD (n = 220, 
10.0%) had a higher representation from the inpatient setting than EoE (n = 122, 5.57%) and was 
therefore significantly more expensive (p<0.001).  
 While few studies exist that compare these three conditions, one study highlights the similarities 
and potential treatment options between them (Molina-Infante et al., 2017). Molina-Infante et al. (2017) 
proposed improving biological disease activity and dietary therapy for patients with chronic inflammatory 
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conditions such as EoE and Crohn’s disease through persistent evaluation and treatment by physicians 
(Molina-Infante et al., 2017). Moreover, the authors agree that long-term diligence in dietary restrictions 
and close monitoring of patients reduces symptoms and inflammation in these patients, thereby improving 
overall quality of life (Molina-Infante et al., 2017). As of this writing, there is no approved biologic 
therapy for EoE. 
 There are several studies that show the impact of EoE on quality of life, which cannot be 
overlooked (Dellon & E.S., 2012; Mukkada et al., 2018; Stern, Taft, Zalewski, Gonsalves, & Hirano, 
2018). Quality of life in terms of emotional and financial burden are often discussed in EoE literature. 
The restrictive diet that often accompanies EoE and induced anxiety from choking on food due to stricture 
or stenosis of the esophagus, have all been documented emotional quality of life limitations (Dellon, 
2014; Stern et al., 2018). Additionally, if impaction occurs, emergency services and an emergency 
endoscopy is often the response, which is a significant financial and emotional burden (Stern et al., 2018). 
This paper presents results that show the cost of this disease per record is just as high as other, more well-
known chronic inflammatory diseases. Males and younger patients are more prevalent in the EoE 
community, whereas females and older patients are more prevalent in the CD and CeD communities.  By 
recognizing that this illness is more prevalent and clinically severe than once proposed, particularly in 
states like Nevada, the quality of life of EoE patients can be greatly improved and the costs reduced.  
Strengths and Weaknesses 
 One limitation for this study includes the inability to calculate true disease prevalence rates from 
the hospital utilization database; as the individual level for analyses is the patient record and not the 
individual. This was why the calculations for cost were done per visit rather than per patient. Repeat visits 
cannot be accounted for in the data making it difficult to determine how many individual patients are truly 
represented within the dataset. Another limitation includes the lack of specialty allergists in Nevada, 
making EoE difficult to capture or diagnose. This further supports the differences seen in treatment and 
diagnosis options between the Northern and Southern regions of the state.  
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 A major strength of this study is the large population size of EoE, CD, and CeD records gathered 
from the CHIA database across multiple years; as well as the large number of CPT codes, cost, and 
demographic differences identified. As these are healthcare utilization data with diagnosis codes, these 
data are typically more accurate than the self-reported data found in some other studies.  
Conclusion 
 The first goal of this study was to identify the overall cost of EoE in the state of Nevada by 
demographics using service charges and CPT codes extracted from a large hospital utilization database. 
Additionally, CPT codes were searched and broken down to identify the most common codes used in the 
Nevadan population for this illness. Significant differences in cost were identified in age, gender, and 
region. Furthermore, CPT codes differed significantly by region, indicating that knowledge about this 
disease and treatment is not consistent across the state. Due to the de-identified nature of the data, it is 
impossible to identify which region has more repeat visits; or if one region exhibits more severe 
symptoms of the disease which could drive up costs. At the time of this writing, only one pediatric 
gastroenterologist doctor was identified in the Northern region, which could indicate a lack of “diversity 
of care” in the Northern region when compared to the Southern Region. Additionally, the increased 
number of allergy specialists in the Southern region more often look for mast cells (as indicated by the 
“special stain and interpretation of report” CPT costs) which could be more costly than procedures in the 
Northern region. Finally, the differences in healthcare premium and reimbursement by region could be 
driving the differences observed. More research is needed to fill these important gaps. 
 A secondary goal included assessing the cost and impact of EoE records relative to two other 
well-known chronic inflammatory conditions, CD and CeD. Significant differences by cost and 
demographic status were identified across the three conditions. The initial number of EoE records 
extracted was far lower than the total number of CD or CeD records identified in the state. However, the 
cost of EoE among several demographic subgroups was substantial. While EoE is considered rare, the 
results presented here show that EoE is just as expensive as other chronic diseases examined in Nevada 
and affects males as well as pediatric patients more often than CD or CED.  
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 In conclusion, the records extracted for this study for CD and CeD have a higher female and adult 
representation. Whereas for EoE higher odds and cost among male and pediatric records was notable. 
When analyzing hospital setting, data for EoE may be viewed as an outpatient disease and therefore 
perceived as less severe when compared to other chronic inflammatory diseases. Based on the data 
presented here, EoE is just as costly per record as CD and CeD in certain demographic subgroups. The 
significant difference in cost and CPT code profile by region suggests that physicians may encounter 
complexities when treating this illness when compared to more well-known diseases.  
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Chapter 5: Summary, Implications, and Conclusions 
5.1 Summary 
 As of this writing, 2,585 published manuscripts referencing EoE were available on PubMed, of 
which, nearly 85% of the articles have been published in the last decade (National Institutes of Health, 
2019).  This disease is still in its infancy and significantly more research needs to be done to complete the 
etiology, therapeutic, and diagnosis gaps that still exist. No studies, to our knowledge, exist that examine 
the risk factors, comorbidities, cost, or impact of EoE within the state of Nevada. While some of the 
results presented in this dissertation mimic already published information, the results also highlight 
several significant and novel features about eosinophilic esophagitis.  
 It is well-described in the literature that, on average, males are at twice the risk of developing 
EoE than females (Dellon & Hirano, 2018). While slightly higher than average, this was the case in 
Nevada as well where 63.7% of the records extracted were labeled male and only 36.3% were female. 
This disease also afflicts those of Caucasian descent more than any other race, another similar factor 
identified in Nevada. Several of the EoE records identified in the CHIA database also exhibited well-
documented comorbidities, including asthma (11.2%), food allergy (2.19%), and eczema (1.55%). 
Finally, identification of EoE in the patient setting via endoscopy was also similar, where over 50% of the 
total records pulled had a recorded endoscopy and follow-on testing.  
 Interestingly, the number of records of EoE identified in Nevada were higher than expected (n = 
2,190). If the diagnosis for this disease is delayed, as hypothesized in Chapter 4, there is a recurrent need 
for emergency endoscopies due to obstruction, which could be driving the record count and cost higher. 
Several climate studies note the wet, cooler regions as having higher rates of EoE, however, Nevada is the 
opposite, typically dry and warm year-round (Dellon, Jensen, et al., 2015; Hurrell et al., 2012). The 
weather in Nevada does however contribute to a longer, more perennial type pollen season (Wong et al., 
2012). Given the well-documented relationship of EoE and atopic illness, Nevada may be a prime region 
to continue studying this disease and could explain the higher than expected record count overall.  
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 Contrary to the published literature, where atopic illness is predominantly reported, the 
comorbidities extracted from the records in Nevada were largely gastric. When all EoE records were 
examined, less than 1% contained common comorbid diagnosis codes for allergic rhinitis, allergic 
conjunctivitis, or sinusitis (Fahey et al., 2017; Kagalwalla et al., 2017; Letner et al., 2018; Longitudinal et 
al., 2015; Moawad et al., 2010; Mohammad et al., 2017; Rodrigues Mariano De Almeida Rezende et al., 
2014; Sugnanam et al., 2007). Comorbidities and sequela extracted from the EoE records in Nevada 
included esophageal obstructions, stricture/stenosis of the esophagus, and hiatal hernias across all 
demographic subgroups examined. This indicates that physicians are either not recognizing the disease 
early enough, or are unsure how to treat it, thereby allowing it to progress.  
 Also contrary to published literature, sensitization to pollen (over 80% of patients) reigned over 
food allergens (less than 20%) in Nevada (Armentia et al., 2018; Fahey et al., 2017; Kagalwalla et al., 
2017; Philpott et al., 2016; Rodrigues Mariano De Almeida Rezende et al., 2014; Slack et al., 2013; 
Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). Due to the perennial pollens reported in the state, it is 
likely that pollen is not washed away often enough, thus resulting in year-round pollen allergies which 
exacerbate EoE symptoms in the population (Patel et al., 2018; Wong et al., 2012). Finally, the cost of 
EoE differed significantly by demographic subgroup, particularly when compared to other well-known 
chronic inflammatory diseases. Males, younger age, region, and hospital setting were all demographic 
factors that set EoE apart from Crohn’s disease and Celiac disease.  
5.2 Strengths and Weaknesses 
 The results in this dissertation were strengthened due to the availability of a statewide hospital 
utilization database. The CHIA database covers all hospital settings in Nevada, both inpatient and 
outpatient, and provides researchers with over 300 variables per dataset. Variables reported by the various 
hospital settings include demographic factors, diagnosis codes, hospital charges, and several important 
public health measures. Many of the results gleaned from this dataset can be interpreted with confidence, 
particularly the charge per record calculations presented in Chapter 4. If necessary, these calculations can 
easily be expanded to calculate the cost of a patient who is seen multiple times a year, or once per year. 
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Another strength includes the complementary dataset provided by UNR SOM. The patient data provided 
includes one patient to one set of skin prick sensitization test results. This dataset gave us the ability to 
calculate sensitization rates for pediatric patients in the state and give us a broad idea of the sensitization 
pattern in Nevada. Using these results, we can confidently conclude that pollen sensitization in Nevada 
far outweighs that of food, as outlined in Chapter 4.   
 This study does not go without limitations. A main limitation of the CHIA database is the 
inability to calculate prevalence rates. The CHIA data filters through the HIPAA State Officer for Nevada 
before distribution to CHIA, ensuring protection and blindness to all personal patient identifiers. 
Therefore, it is near impossible to calculate an accurate prevalence rate for Chapter 2 because repeat visits 
cannot be accounted for with this data. As mentioned in Chapter 3, some patients with more progressed 
illness may visit a gastroenterologist multiple times per year for esophageal stricture or stenoses. 
Additionally, because this is clinical data there are several variables missing across all datasets. Marital 
status was absent, while race, gender, and age all had several missing values across all records. Between 
datasets variables differed as well; variables available across all datasets had to be selected before 
combining the final dataset. Finally, human error is always a potential limitation when dealing with data 
entry. If a code is entered incorrectly, or into the wrong category, the record will not be pulled during 
exploratory data analysis. This is particularly true for high-paced hospitalization areas such as the 
emergency and surgery departments.  
5.3 Orphan Diseases and the Necessity of Advocacy Groups 
 Rare diseases, such as EoE, are often referred to as “orphan diseases” due to the lack of funding, 
little public awareness, and dependency on advocacy groups for support (No authors listed, 2008). Rare 
diseases have several definitions, but on average, affect fewer than 7 out of 10,000 individuals in a 
population (Valdez, Grosse, & Khoury, 2016). While the prevalence for rare diseases is low, studies show 
that individuals admitted as an inpatient stay three days longer than those admitted under more well-
known conditions (Valdez et al., 2016). It is hypothesized that nearly 80% of the 5,000-8,000 rare 
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diseases that exist have an associated genetic component, which could be invaluable given the right 
amount of time and funding (Valdez et al., 2016). 
 The results presented here could help fill several knowledge gaps, as well as advance research 
through several advocacy groups that currently work with EoE patients and researchers. Advocacy groups 
include: American Partnership for Eosinophilic Disorders (APFED), National Organization for Rare 
Disorders (NORD), and American Academy of Allergy, Asthma, & Immunology (AAAAI). Each one of 
these groups is a professional organization with specialized physician, caretaker, and patient involvement 
that distributes research grants and holds annual meetings to disseminate information about rare diseases 
(American Academy of Allergy Asthma & Immunology, 2019; American Partnership for Eosinophilic 
Disorders, 2019; National Organization for Rare Disorders, 2019). As a result of the efforts of these 
advocacy groups, diagnosis and treatment guidelines have been developed and ICD codes created for 
several rare conditions (James & Assa’ad, 2018). Several studies argue that rare diseases, such as EoE, 
require advocacy groups to continue driving knowledge forward (Badiu et al., 2017; James & Assa’ad, 
2018). Additionally, advocacy groups allow for transparency for patients via readily available knowledge, 
as well as drives physician education forward as patients ask more questions about the disease they face 
(James & Assa’ad, 2018).   
5.4 Public Health Implications and Limitations 
 There are public health strategies that should be considered based on the results presented here 
for EoE and other rare diseases identified in the state of Nevada. Valdez et al. outlines an important public 
health operational framework for rare diseases which directly correlates to the main discussion points in 
this dissertation (Valdez et al., 2016).  This framework first describes the necessity for the assessment of 
burden of the disease, including identifying the number of affected individuals, expected health outcomes, 
overall quality of life, a health-care use summary, and overall economic cost (Valdez et al., 2016).  This 
first component was thoroughly discussed in this dissertation in Chapters 2 and 4 for the state of Nevada 
in this dissertation. The second component presented by Valdez describes the importance of research on 
preventable causes and effective treatments for rare diseases (Valdez et al., 2016). As discussed in 
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Chapter 3, it is well documented that EoE and atopy share a relationship, therefore, reducing the exposure 
to potential allergens through either medications or food elimination diets would help reduce the overall 
patient symptomology and burden. Earlier identification of the disease would reduce the gastric 
component identified in Chapter 3 and the overall burden to the patient. Furthermore, while research is 
ongoing through the various advocacy groups throughout the country, no EoE research in Nevada is 
currently funded.  
 The third, fourth, and fifth components include: systems for screening and early identification of 
rare diseases (3), empowerment and education of people with rare diseases (4), and public policies that 
promote access to services and treatments for those diagnosed with rare diseases (5) (Valdez et al., 2016). 
These last components described by Valdez et al. are not only limited in the EoE literature, but do not 
exist in Nevada. Screening and identification of EoE is limited in Nevada and based largely on physician 
knowledge of the disease. As discussed in Chapter 3, many of the EoE diagnoses in the state are made 
once the disease has progressed to severe stages. At this point, only one physician is listed on APFED’s 
site for the entire state of Nevada that specializes in EoE (APFED, 2019). This severely limits the 
likelihood of EoE being diagnosed without prior knowledge or expertise anywhere else in the state.  
 According to NORD rare disease policy is severely lacking in Nevada (NORD, 2019).  For those 
suffering from a rare disease, Nevada received a “Fail” grade for out-of-pocket prescription protections 
and individual insurance protections (NORD, 2019). The state received a “C” grade for Newborn 
screenings, indicating that the state does not screen for all of the recommended uniform screening panel 
(RUSP) core conditions (NORD, 2019). Finally, Nevada received an “Incomplete” for the development of 
a rare disease advisory council or caucus (NORD, 2019).  Given the low grades for rare disease support in 
Nevada, combined with the lack of knowledge and limited number of physicians available, changes are 
necessary for this population. Importance should be placed on all chronic diseases in the state as well as 
availability, access, and knowledge for those suffering from rare diseases.  
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5.5 Conclusions 
 Eosinophilic esophagitis in Nevada is largely overlooked by many physicians. The main goal of 
this dissertation was to define the state of EoE in Nevada, identify associated risk factors and 
comorbidities, as well put the severity of this disease into context by comparing EoE to other chronic 
illnesses. So often rare diseases go unnoticed due to the lack of knowledge or funding. It is our hope that 
these results are disseminated to help improve the knowledge gap that exists for EoE in Nevada and helps 
shed light on this disease globally. 
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Appendix A: EoE CHIA Codebook for analysis in R 
ITEM 1.    
Variable name:  Hospital Setting 
Variable label:  hs 
Variable type:  nominal, categorical 
Missing values:  no 
Description of item: Hospital setting: asc = ambulatory surgery center, er = outpatient emergency,  
ip = inpatient, thos= other outpatient & outpatient surgery 
 
ITEM 2.    
Variable name:  Diagnosis Level 
Variable label:  diaglvl 
Variable type:  ordinal, continuous 
Missing values:  yes 
Description of item: EoE is present in diagnosis levels 1 – 33; Only Diag01-04 will be utilized 
 
ITEM 3.    
Variable name:  Admit Year 
Variable label:  ayear 
Variable type:  ordinal, continuous / OR categorical 
Missing values:  no 
Description of item: Year of admittance to hospital setting 
 
ITEM 4. 
Variable name:  Discharge Year 
Variable label:  dischyear 
Variable type:  ordinal, continuous / OR categorical 
Missing values:  no 
Description of item: Year of discharge 
 
ITEM 5.  
Variable name:  Patient Zip Code 
Variable label:  patzip 
Variable type:  discrete continuous 
Missing values:  yes 
Description of item: Zip codes of the patient’s home of record.  
   0: Unknown/Mis-entered/incorrect (89071 – thos – OO# 1007) 
 
ITEM 6.    
Variable name:  Race 
Variable label:  race 
Variable type:  nominal categorical 
Missing values:  no 
Description of item: Race of the patient 
1: Native American or Alaskan 
2: Asian or Pacific Islander 
3: Black/African American 
4: White/Caucasian 
5: Hispanic 
6: Other/Unknown 
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ITEM 7.    
Variable name:  Age in years 
Variable label:  age 
Variable type:  ordinal continuous 
Missing values:  no 
Description of item: Age listed on record upon admission to the setting of interest 
 
ITEM 8.    
Variable name:  Gender of patient 
Variable label:  gender 
Variable type:  nominal categorical 
Missing values:  no 
Description of item: Sex listed on record upon admission to the setting of interest 
1: Female 
2: Male 
 
ITEM 9.    
Variable name:  Admit Type  
Variable label:  atype 
Variable type:  nominal categorical 
Missing values:  no 
Description of item: Admit type  
1: Emergency 
2: Urgent 
3: Elective 
9: Unknown 
 
ITEM 10.    
Variable name:  Length of Stay (only in Inpatient dataset) 
Variable label:  los 
Variable type:  continuous 
Missing values:  no 
Description of item: Length of stay (in days) of patients as an inpatient 
 
ITEM 11.    
Variable name:  Total Charge 
Variable label:  totalcharge 
Variable type:  continuous 
Missing values:  no 
Description of item: Total cost owed to the hospital setting for services provided 
 
ITEM 12.    
Variable name:  Diagnosis Codes 01-04 (ICD-9 or ICD-10 codes) 
Variable label:  diag01 – diag4 
Variable type:  nominal categorical 
Missing values:  yes 
Description of item: List of ICD-9 and ICD-10 diagnosis codes for each record  
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ITEM 13.    
Variable name:  Procedure Codes (inpatient only; same as ICD-9 or ICD-10 diagnosis codes) 
Variable label:  proc01 – proc04 
Variable type:  nominal categorical 
Missing values:  yes 
Description of item: ICD-9 and ICD-10 procedure codes listed for patients that had procedures done  
   in the hs. 
 
ITEM 14.    
Variable name:  Hospital Revenue Codes 
Variable label:  rev01 – rev04 
Variable type:  continuous 
Missing values:  yes 
Description of item: Revenue codes for hospital billing – defines which part of the hospital billed. 
 
ITEM 15.    
Variable name:  Hospital CPT codes (procedure codes) 
Variable label:  CPT01 – CPT04 
Variable type:  nominal categorical 
Missing values:  yes 
Description of item: Labels for the hospital CPT codes/procedure performed 
 
ITEM 16.    
Variable name:  Service Charges to patient/insurance company 
Variable label:  Srv01-Srv04 
Variable type:  continuous 
Missing values:  yes 
Description of item: Number of specific times each service was performed. 
 
ITEM 17.    
Variable name:  Charges to patient/insurance company 
Variable label:  Charge01-Charge04 
Variable type:  continuous  
Missing values:  yes 
Description of item: Total cost of procedures and medical equipment  
 
ITEM 18.    
Variable name:  Original CHIA ID number 
Variable label:  CHIAID 
Variable type:  nominal 
Missing values:  none 
Description of item: The original name of the record in the CHIA datasets. 
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